Anti-egfr antibody and anti-c-met/anti-egfr bispecific antibodies comprising the same

ABSTRACT

An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of Korean Patent Application No. 10-2013-0089280 filed on Jul. 29, 2013 in the Korean Intellectual Property Office, the entire disclosure of which is hereby incorporated by reference.

INCORPORATION-BY-REFERENCE OF MATERIAL ELECTRONICALLY SUBMITTED

Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted herewith and identified as follows: 142,989 bytes ASCII (Text) file named “718050 ST25.TXT,” created Jul. 29, 2014.

BACKGROUND

1. Field

Provided are an anti-EGFR antibody or antigen binding fragment thereof, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same.

2. Description of the Related Art

c-Met and EGFR (or HER family) interact with each other and are involved in various mechanisms related to tumors. These proteins (targets) are typical receptor tyrosine kinases (RTKs) present at the surface of cells, thereby inducing the proliferation of cancer cells, the penetration of the cancer cells, angiogenesis, etc. Also, these proteins participate in each other's signal transduction systems by interacting with each other, thereby inducing resistance against each other's therapeutic agents.

Meanwhile, multispecific antibodies targeting two or more antigens have been developed in various kinds and forms and are expected as a new drug antibody having excellent therapeutic effects compared to a monoclonal antibody. Most multispecific antibodies have been developed so that their therapeutic effects on cancers can be increased by recognizing an antigen of cytotoxic cells (killer cells) and another antigen of cancer cells at the same time thus allowing the cancer cells to be killed by the cytotoxic cells. However, when considering that the research results reveal that cancer cells themselves can be mutated to proliferate and penetrate even by intracellular ligands or various antigens of the same cancer cells other than the targeted antigen, it is expected that a multispecific antibody capable of recognizing another antigen of the cancer cells as well as an antigen of the killer cells will be also useful in treating cancers.

Accordingly, there is a need for the development of a multispecific antibody which is predicted to achieve effective cancer treatment by recognizing two or more kinds of antigens in cancer cells at the same time (e.g., a bispecific antibody).

SUMMARY

One embodiment provides a polypeptide including one amino acid sequence or a combination of two or more amino acid sequences selected from the group consisting of SEQ ID NO: 109 to SEQ ID NO: 114.

Another embodiment provides an anti-EGFR antibody or an antigen-binding fragment thereof comprising or consisting essentially of at least one heavy chain complementarity determining region selected from the group consisting of CDR-H1 including the amino acid sequence of SEQ ID NO: 109, CDR-H2 including the amino acid sequence of SEQ ID NO: 110, and CDR-H3 including the amino acid sequence of SEQ ID NO: 111; at least one light chain complementarity determining region selected from the group consisting of CDR-L1 including the amino acid sequence of SEQ ID NO: 112, CDR-L2 including the amino acid sequence of SEQ ID NO: 113, and CDR-L3 including the amino acid sequence of SEQ ID NO: 114; or a combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region.

Another embodiment provides an anti-c-Met/anti-EGFR bispecific antibody including an anti-c-Met antibody or an antigen-binding fragment thereof and an anti-EGFR antibody or an antigen-binding fragment thereof, wherein the anti-c-Met antibody or an antigen-binding fragment thereof specifically binds to an epitope including 5 or more contiguous amino acids within SEMA domain (SEQ ID NO: 79) of c-Met protein, and the anti-EGFR antibody or an antigen-binding fragment thereof includes at least one heavy chain complementarity determining region selected from the group consisting of CDR-H1 including the amino acid sequence of SEQ ID NO: 109, CDR-H2 including the amino acid sequence of SEQ ID NO: 110, and CDR-H3 including the amino acid sequence of SEQ ID NO: 111; at least one light chain complementarity determining region selected from the group consisting of CDR-L1 including the amino acid sequence of SEQ ID NO: 112, CDR-L2 including the amino acid sequence of SEQ ID NO: 113, and CDR-L3 including the amino acid sequence of SEQ ID NO: 114; or a combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region.

Another embodiment provides a pharmaceutical composition including the polypeptide or the anti-c-Met/anti-EGFR bispecific antibody as an active ingredient.

Another embodiment provides a pharmaceutical composition for preventing and/or treating a cancer including the anti-c-Met/anti-EGFR bispecific antibody as an active ingredient.

Another embodiment provides a method of preventing and/or treating a cancer including administering a pharmaceutically effective amount of the anti-c-Met/anti-EGFR bispecific antibody to a subject in need of preventing and/or treating a cancer.

Additional compositions and methods are described in the following sections.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 is a schematic of an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment.

FIG. 2 is a size exclusion chromatography displaying a monomeric property of the purified anti-c-Met/anti-EGFR bispecific antibody according to an embodiment.

FIG. 3 is a graph displaying the binding affinities to EGFR and c-Met of an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment.

FIG. 4A is a graph displaying the cell growth of various cancer cells treated with antibodies including an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment, which is calculated as a relative value to that of a control (media, without antibody).

FIG. 4B is a graph displaying the cell growth of various cancer cells treated with antibodies including an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment, which is calculated as a relative value to that of a control (media, without antibody).

FIG. 4C is a graph displaying the cell growth of various cancer cells treated with antibodies including an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment, which is calculated as a relative value to that of a control (media, without antibody).

FIG. 4D is a graph displaying the cell growth of various cancer cells treated with antibodies including an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment, which is calculated as a relative value to that of a control (media, without antibody).

FIG. 4E is a graph displaying the cell growth of various cancer cells treated with antibodies including an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment, which is calculated as a relative value to that of a control (media, without antibody).

FIG. 4F is a graph displaying the cell growth of various cancer cells treated with antibodies including an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment, which is calculated as a relative value to that of a control (media, without antibody).

FIG. 5 is a graph displaying the cell growth of resistance-induced cells (HGF treated N87 cell (upper) and NCI-H820 cell (lower)) when treated with antibodies including an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment.

FIG. 6 is an immunoblot showing the phosphorylation and degradation of c-Met and EGFR when treated with antibodies including an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment.

FIG. 7 provides fluorescence microscopic images of SNU638 gastric cancer cells showing co-localization of c-Met and EGFR after treating an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment.

FIG. 8 consists of graphs displaying the expression levels of c-Met and EGFR when treated with an anti-c-Met antibody or with anti-c-Met/anti-EGFR bispecific antibody according to an embodiment, indicating the degradation of both of c-Met and EGFR by the anti-c-Met/anti-EGFR bispecific antibody.

FIG. 9 consists of graphs displaying comparative cell migration level of SNU638 gastric cancer cells when treated with an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment which is calculated as a relative value to that of a control (media, without antibody).

FIG. 10 is a graph displaying tumor volume change in a mouse xenograft model when treated with an anti-c-Met/anti-EGFR bispecific antibody according to an embodiment showing in vivo anti-tumor efficacy of bispecific antibody in animal cancer model.

DETAILED DESCRIPTION

The existing drugs which recognize only EGFR, a typical target widely expressed on cancer cells, induce over-expression and mutation of c-Met, allowing cancer cells to acquire resistance against the drugs, whereby the therapeutic effects of the drugs could be reduced. In this regard, in the present invention, it is verified that a bispecific antibody recognizing c-Met and EGFR at the same time prevents the development of resistance and shows excellent cancer cell inhibitory effects, even in cancer cells having resistance, by previously blocking c-Met-implicated signal transduction which causes resistance against drugs.

Although various bispecific antibodies have been developed, their efficiency was not proved in clinical tests or their several side effects were observed. For these reasons, there were many cases which were not approved by FDA and were not marketed as therapeutic antibodies. In spite of the fact that bispecific antibodies having various forms and mechanisms have been developed, the bispecific antibodies were not marketed due to a problem in the stability and productivity of the antibodies. In the production of early bispecific antibodies having an IgG form, due to random combination between light chains and heavy chains of antibodies, it is very difficult to separate and purify a desired kind of bispecific antibody, which becomes an obstacle in the mass production. Also, in the case of bispecific antibodies with non-IgG forms, their stabilities as a drug were not verified in protein folding, pharmacokinetics, and the like. In the present invention, it is verified that a bispecific antibody in which an anti-c-Met antibody is fused to an antibody recognizing a secondary target, EGFR, or an antigen binding fragment thereof (e.g., scFv) could improve and address the stability issue, which was the biggest problem of the pre-existing bispecific antibodies.

One embodiment provides a polypeptide including a novel amino acid sequence. The polypeptide may function as a CDR of an anti-EGFR antibody. In particular, the polypeptide may include one amino acid sequence or a combination of two or more amino acid sequences selected from the group consisting of SEQ ID NO: 109 to SEQ ID NO: 114. The function of the polypeptide including the amino acid sequence of SEQ ID NO: 109 to SEQ ID NO: 114 as a CDR of an anti-EGFR antibody is summarized in Table 1, as follows:

TABLE 1 Heavy chain CDR Light chain CDR CDR- NYDMS CDR- TGSSSNIGNNDVS H1 (SEQ ID NO: 109) Ll (SEQ ID NO: 112) CDR- GISHSSGSKYYADSVKG CDR- DDNKRPS H2 (SEQ ID NO: 110) L2 (SEQ ID NO: 113) CDR- KDATPRPLKPFDY CDR- GSWDASLNA H3 (SEQ ID NO: 111) L3 (SEQ ID NO: 114)

In one particular embodiment, the polypeptide may a polypeptide including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, a polypeptide including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, or a combination thereof. The polypeptide including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, that includes the amino acid sequences of SEQ ID NOS: 109 to 111, and may have a function as a heavy chain variable region of an anti-EGFR antibody. In addition, the polypeptide including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, that includes the amino acid sequences of SEQ ID NOS: 112 to 114, and may have a function as a light chain variable region of an anti-EGFR antibody.

<SEQ ID NO: 115, capable of acting as a heavy chain variable region of an anti-EGFR antibody>

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMSWVRQAPGKGLE                                CDR-H1 WVSGISHSSGSKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY          CDR-H2 YCAKDATPRPLKPFDYWGQGTLVTVSS       CDR-H3

(wherein, the CDRs are marked in bold type)

<SEQ ID NO: 116, capable of acting as a light chain variable region of an anti-EGFR antibody>

QSVLTQPPSASGTPGQRVTISCTGSSSNIGNNDVSWYQQLPGTAPKLLI                            CDR-L1 YDDNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCGSWDASL   CDR-L2                                  CDR-L3 NAYVFGGGTKLTVLG

(wherein, the CDRs are marked in bold type)

<SEQ ID NO: 117, capable of acting as a heavy chain variable region of an anti-EGFR antibody >

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMSWVRQAPGKCLEW                                CDR-H1 VSGISHSSGSKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY        CDR-H1 CAKDATPRPLKPFDYWGQGTLVTVSS      CDR-H1

(wherein, the CDRs are marked in bold type)

<SEQ ID NO: 118, capable of acting as a heavy chain variable region of an anti-EGFR antibody >

QSVLTQPPSASGTPGQRVTISCTGSSSNIGNNDVSWYQQLPGTAPKLLI                            CDR-L1 YDDNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCGSWDASL   CDR-L2                                  CDR-L3 NAYVFGCGTKLTVLG

(wherein, the CDRs are marked in bold type)

The polypeptide may act as a precursor or a component of an EGFR antagonist, such as an anti-EGFR antibody, an antigen-binding fragment thereof, or an anti-EGFR antibody analog (e.g., a peptibody, nanobody, etc.).

Therefore, another embodiment provides an anti-EGFR antagonist including the polypeptide. The antagonist inhibits the EGFR activity, and may be one or more selected from the group consisting of an anti-EGFR antibody, an antigen-binding fragment thereof, an anti-EGFR antibody analogue (e.g., a peptibody, nanobody, etc.), and the like.

The term “antagonist” may include any molecule capable of completely or partially preventing, inhibiting, or neutralizing one or more biological activities of a target (e.g., EGFR). For instance, an antibody as an antagonist may refer to an antibody capable of inhibiting or lowering biological activities of an antigen (e.g., EGFR) to which the antibody binds. The antagonist may bind to a receptor for a ligand (target) to decrease receptor phosphorylation, or incapacitating or killing a cell that is activated by the ligand. In addition, the antagonist may substantially decrease an interaction between a receptor and its ligand, by completely blocking the receptor-ligand interaction, binding to the receptor competitively with its ligand, or modifying or down-regulating three-dimensional structure of the receptor.

Term “peptibody (peptide+antibody)” may refer to a fusion protein wherein a peptide is fused with the whole or a part of a constant region of an antibody, such as Fc region, and the peptide acts as an antigen-binding region (e.g., a CDR or variable region of a heavy chain and/or light chain), thereby having a structure and functions similar to an antibody.

Term “nanobody” that is also called as a single-domain antibody, may refer to an antibody fragment including a single variable domain in a monomeric form and selectively binding to a specific antigen, similarly to an antibody in a complete form. The nanobody usually has a molecular weight of about 12 kDa to about 15 kDa, which is much smaller than an general molecular weight (about 150 kDa to about 160 kDa) of an antibody in a complete form (including two heavy chains and two light chains), and in some case, smaller than a molecular weight of a Fab fragment or a scFv fragment.

In a particular embodiment, the polypeptide may act as a precursor or a component of an anti-EGFR antibody.

Another embodiment provides an anti-EGFR antibody or an antigen-binding fragment thereof including the polypeptide. The antigen-binding fragment may be selected from the group consisting of scFv, (scFv)2, scFv-Fc, Fab, Fab′ and F(ab′)2.

In particular, the anti-EGFR antibody or an antigen-binding fragment thereof may comprise or consist essentially of:

at least one heavy chain complementarity determining region selected from the group consisting of CDR-H1 including the amino acid sequence of SEQ ID NO: 109, CDR-H2 including the amino acid sequence of SEQ ID NO: 110, and CDR-H3 including the amino acid sequence of SEQ ID NO: 111, or a heavy chain variable region including the at least one heavy chain complementarity determining region;

at least one light chain complementarity determining region selected from the group consisting of CDR-L1 including the amino acid sequence of SEQ ID NO: 112, CDR-L2 including the amino acid sequence of SEQ ID NO: 113, and CDR-L3 including the amino acid sequence of SEQ ID NO: 114 or a light chain variable region including the at least one light chain complementarity determining region;

a combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region; or

a combination of the heavy chain variable region and the light chain variable region.

For example, the anti-EGFR antibody or an antigen-binding fragment thereof may comprise or consisting essentially of a heavy chain variable region including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, a light chain variable region including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, or a combination thereof.

In a particular embodiment, the anti-EGFR antibody or an antigen-binding fragment thereof may be an anti-EGFR scFv comprising or consisting essentially of a heavy chain variable region including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, and a light chain variable region including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118.

In the polypeptide or an anti-EGFR scFv comprising or consisting essentially of a heavy chain variable region including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, and a light chain variable region including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, the heavy chain variable region and the light chain variable region may be linked with or without a linker (e.g., a peptide linker). The peptide linker may be those including any amino acids of 1 to 100, particularly 2 to 50, and any kinds of amino acids may be included without any restrictions. The peptide linker may include for example, Gly, Asn and/or Ser residues, and also include neutral amino acids such as Thr and/or Ala. Amino acid sequences suitable for the peptide linker may be those known in the relevant art. Meanwhile, a length of the peptide linker may be variously determined within such a limit that the functions of the fusion protein will not be affected. For instance, the peptide linker may be formed by including a total of about 1 to about 100, about 2 to about 50, or about 5 to about 25 of one or more selected from the group consisting of Gly, Asn, Ser, Thr, and Ala. In one embodiment, the peptide linker may be represented as GGGGS_(n) (n is an integer of about 1 to about 10, particularly an integer of about 2 to about 5).

As used herein, the term “antibody” may refer to a substance generated by a stimulation of an antigen in immune system, and there is no specific limitation in its kinds. The antibody may include all of an animal antibody, a chimeric antibody, a humanized antibody, and a human antibody. In addition the antibody may include an antigen-binding fragment derived from an antibody having an antigen binding affinity. The “complementarity-determining region (CDR)” may refer to a region within a variable region, which give a binding specificity to an antigen. The antigen-binding fragment as described above may be an antibody fragment including at least one complementarity-determining region, for example, one or more selected from the group consisting of scFv, (scFv)2, scFv-Fc, Fab, Fab′, and F(ab′)2.

In the anti-EGFR antibody or an antigen-binding fragment thereof, the rest portion of the light chain and the heavy chain portion excluding the CDRs, the light chain variable region, and the heavy chain variable region as defined above, e.g., a light chain constant region and a heavy chain constant region, may be those from any subtype of immunoglobulin (e.g., IgA, IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4), IgM, and the like).

Based on the ability of specifically binding to EGFR, the anti-EGFR antibody or an antigen-binding fragment thereof may be used in detecting EGFR or confirming activation and/or overproduction (i.e. overexpression) of EGFR.

One embodiment provides a composition for detecting the presence of EGFR including the anti-EGFR antibody or an antigen-binding fragment thereof. Another embodiment provides a method of detecting EGFR including treating a biological sample with the anti-EGFR antibody or an antigen-binding fragment thereof and detecting an antigen-antibody reaction (binding). In the method of detecting, when an antigen-antibody reaction is detected, it can be determined that EGFR is present in the biological sample. Another embodiment provides a use of the anti-EGFR antibody or an antigen-binding fragment thereof for detecting EGFR. The biological sample may be selected from the group consisting of a cell, a tissue, a body fluid (e.g., blood, serum, etc.), and the like derived from a mammal including primates such as a human, a monkey, and the like, or a rodent such as a mouse, a rat, and the like. The biological sample may be separated from a living body. The detection of EGFR may refer to detection of presence EGFR, expression of EGFR, or the level of EGFR.

Another embodiment provides a pharmaceutical composition for diagnosing activation and/or overproduction of EGFR or a disease associated with activation and/or overproduction of EGFR including the anti-EGFR antibody or an antigen-binding fragment thereof. Another embodiment provides a method of diagnosing (or determining) activation and/or overproduction of EGFR or a disease associated with activation and/or overproduction of EGFR, including treating a biological sample derived from a patient with the anti-EGFR antibody or an antigen-binding fragment thereof, and measuring a level of an antigen-antibody reaction. In this method, when the level of the antigen-antibody reaction in the biological sample is higher than that of a normal sample, the patient from which the biological sample is derived may be determined as having activation and/or overproduction of EGFR or a disease associated with activation and/or overproduction of EGFR. Therefore, the method may further include treating a normal sample with the anti-EGFR antibody or an antigen-binding fragment thereof, and measuring a level of an antigen-antibody reaction.

The biological sample may be at least one selected from the group consisting of a cell, a tissue, fluid (e.g., blood, serum, and the like) and the like, derived from a patient to be diagnosed. The biological sample may be separated from a living body. The normal sample may be at least one selected from the group consisting of a cell, a tissue, fluid (e.g., blood, serum, and the like) and the like, derived from a patient having no condition of activation and/or overproduction of EGFR or a disease associated with activation and/or overproduction of EGFR. The normal sample may be separated from a living body. The patient may be selected from a mammal, including primates such as a human, a monkey, and the like, and rodents such as a mouse, a rat, and the like.

Another embodiment provides an anti-c-Met/anti-EGFR bispecific antibody including an anti-c-Met antibody or an antigen-binding fragment thereof and an anti-EGFR antibody or an antigen-binding fragment thereof. The antigen-binding fragment thereof may be selected from the group consisting of scFv, (scFv)2, scFvFc, Fab, Fab′, and F(ab′)2.

The “c-Met protein” refers to a receptor tyrosine kinase binding to hepatocyte growth factor. The c-Met proteins may be derived from any species, for example, those derived from primates such as human c-Met (e.g., NP_(—)000236) and monkey c-Met (e.g., Macaca mulatta, NP_(—)001162100), or those derived from rodents such as mouse c-Met (e.g., NP_(—)032617.2) and rat c-Met (e.g., NP_(—)113705.1). The proteins include, for example, a polypeptide encoded by the nucleotide sequence deposited under GenBank Accession Number NM_(—)000245, or a protein encoded by the polypeptide sequence deposited under GenBank Accession Number NM_(—)000236, or extracellular domains thereof. The receptor tyrosine kinase c-Met is involved in several mechanisms including cancer incidence, cancer metastasis, cancer cell migration, cancer cell penetration, angiogenesis, etc.

The “EGFR (epidermal growth factor receptor)” is a member of the receptor tyrosine kinases (RTKs) of HER family. The binding of a ligand to the extracellular domain of EGFR induces receptor homo- or hetero dimerization with other ErbB receptors, which in turn results in intracellular self-phosphorylation of specific tyrosine residues. EGFR self-phosphorylation leads to downstream signal transduction networks including MAPK and PI3K/Akt activation which affects cell proliferation, angiogenesis and metastasis. Over-expression, gene amplification, mutation, or rearrangement of EGFR are frequently observed in several human malignant tumors and are related to poor prognosis of cancer treatment and bad clinical outcomes. For such reasons, the EGFR becomes an important target in anticancer therapy. The EGFR or HER2 may be derived from mammals, for example, primates such as humans and monkeys, or rodents such as rats and mice. For instance, the EGFR may be polypeptides encoded by the nucleotide sequences (mRNA) deposited under GenBank Accession Nos. JQ739160, JQ739161, JQ739162, JQ739163, JQ739164, JQ739165, JQ739166, JQ739167, NM_(—)005228.3, NM_(—)201284.1, NM_(—)201282.1, or NM_(—)201283.1.

In one embodiment, the anti-c-Met/anti-EGFR bispecific antibody may include an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-EGFR antibody or an antigen binding fragment thereof which is linked to the C terminus or N terminus, for example, C terminal, of the anti-c-Met antibody or the antigen binding fragment thereof.

In the anti-c-Met/anti-EGFR bispecific antibody, in order to fully perform the anti-c-Met antibody's activity to mediate intracellular migration and degradation of c-Met proteins, it may be advantageous that the anti-c-Met antibody has its own intact antibody structure. In addition, in case of the anti-EGFR antibody, its specific recognition and binding to EGFR is important, and thus it will be fine that just an antigen-binding fragment recognizing EGFR is included in the bispecific antibody. Therefore, the anti-c-Met/anti-EGFR bispecific antibody may be those including a complete form of an anti-c-Met antibody (e.g., IgG type antibody) and an antigen binding fragment of the anti-EGFR antibody linked to the C terminus of the anti-c-Met antibody.

In the anti-c-Met/anti-EGFR bispecific antibody, the anti-c-Met antibody or the antigen binding fragment thereof, and the anti-EGFR antibody or the antigen binding fragment thereof, may be linked via a peptide linker, or they may be linked directly and without a linker. Furthermore, a heavy chain portion and a light chain portion within the antigen binding fragment, for example, a heavy chain variable region and a light chain variable region within the scFv fragment, may be linked via a peptide linker or without a linker The peptide linker which links the anti-c-Met antibody or the antigen binding fragment thereof and the anti-EGFR antibody or the antigen binding fragment thereof, and the peptide linker which links the heavy chain portion and the light chain portion within the antigen binding fragment, may be identical or different. The peptide linker may be include about 1 to about 100 amino acid residues, particularly about 2 to about 50, and any kinds of amino acids may be included without any restrictions. The peptide linker may include for example, Gly, Asn and/or Ser residues, and also include neutral amino acids such as Thr and/or Ala. Amino acid sequences suitable for the peptide linker may be those known in the pertinent art. Meanwhile, a length of the peptide linker may be variously determined within such a limit that the functions of the fusion protein will not be affected. For instance, the peptide linker may be formed by including a total of about 1 to about 100, about 2 to about 50, or about 5 to about 25 of one or more selected from the group consisting of Gly, Asn, Ser, Thr, and Ala. In one embodiment, the peptide linker may be represented as (GGGS)_(n) (n is an integer of about 1 to about 10, particularly an integer of about 2 to about 5).

In a particular embodiment, the anti-EGFR antibody or an antigen-biding fragment may comprise or consist essentially of:

at least one heavy chain complementarity determining region selected from the group consisting of CDR-H1 including the amino acid sequence of SEQ ID NO: 109, CDR-H2 including the amino acid sequence of SEQ ID NO: 110, and CDR-H3 including the amino acid sequence of SEQ ID NO: 111 or a heavy chain variable region including the at least one heavy chain complementarity determining region;

at least one light chain complementarity determining region selected from the group consisting of CDR-L1 including the amino acid sequence of SEQ ID NO: 112, CDR-L2 including the amino acid sequence of SEQ ID NO: 113, and CDR-L3 including the amino acid sequence of SEQ ID NO: 114 or a light chain variable region including the at least one light chain complementarity determining region;

a combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region; or

a combination of the heavy chain variable region and the light chain variable region.

For example, the anti-EGFR antibody or an antigen-binding fragment thereof may comprise or consist essentially of a heavy chain variable region including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, a light chain variable region including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, or a combination thereof.

In a particular embodiment, the anti-EGFR antibody or an antigen-binding fragment thereof may be an anti-EGFR scFv including a heavy chain variable region including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, and a light chain variable region including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118.

The “antigen binding fragment” refers to a fragment of a full immunoglobulin structure including parts of the polypeptide including a portion capable of binding to an antigen. For example, it may be scFv, (scFv)₂, Fab, Fab′, or F(ab′)₂, but not be limited thereto. In the present invention, the antigen binding fragment may be an antibody fragment including at least one complementarity determining region, for example, selected from the group consisting of scFv, (scFv)2, scFv-Fc, Fab, Fab′ and F(ab′)2.

Of the antigen binding fragments, Fab is a structure having variable regions of a light chain and a heavy chain, a constant region of the light chain, and the first constant region (C_(H1)) of the heavy chain, and it has one antigen binding site.

Fab′ is different from Fab in that it has a hinge region including one or more cysteine residues at the C-terminal of heavy chain C_(H1) domain. An F(ab′)₂ antibody is formed through disulfide bond of the cysteine residues at the hinge region of Fab′.

Fv is a minimal antibody piece having only a heavy chain variable region and light chain variable region, and a recombinant technique for producing the Fv fragment is well known in the pertinent art. Two-chain Fv may have a structure in which the heavy chain variable region is linked to the light chain variable region by a non-covalent bond, and single-chain Fv (scFv) may generally have a dimer structure as in the two-chain Fv in which the variable region of a heavy chain and the variable region of a light chain are covalently linked via a peptide linker or they are directly linked to each other at the C-terminal thereof. The peptide linker may be the same as described in the above.

The antigen binding fragments may be obtained using proteases (for example, a whole antibody is digested with papain to obtain Fab fragments, and is digested with pepsin to obtain F(ab′)₂ fragments), and may be prepared by a genetic recombinant technique.

In a particular embodiment, the anti-c-Met/anti-EGFR bispecific antibody may be those including an anti-c-Met antibody, and scFv, (scFv)₂, Fab, Fab′ or F(ab′)₂, for example, scFv, of the anti-EGFR antibody linked to the C terminus of the anti-c-Met antibody. For instance, scFv, (scFv)₂, Fab, Fab′ or F(ab′)₂ of the anti-EGFR antibody may be those including a heavy chain variable region including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117 and a light chain variable region including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118.

In a particular embodiment, the anti-c-Met/anti-EGFR bispecific antibody may be those including the anti-c-Met antibody, and scFv, (scFv)₂, Fab, Fab′ or F(ab′)₂ of the anti-EGFR antibody including a heavy chain variable region including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117 and a light chain variable region including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, linked to the C terminal of the anti-c-Met antibody.

The anti-c-Met antibody may be any one recognizing a specific region of c-Met, e.g., a specific region in the SEMA domain, as an epitope. It may be any antibody or antigen-binding fragment that acts on c-Met to induce intracellular internalization and degradation of c-Met.

c-Met, a receptor for hepatocyte growth factor(HGF), may be divided into three portions: extracellular, transmembrane, and intracellular. The extracellular portion is composed of an α-subunit and a β-subunit which are linked to each other through a disulfide bond, and contains a SEMA domain responsible for binding HGF, a PSI domain (plexin-semaphorins-integrin homology domain) and an IPT domain (immunoglobulin-like fold shared by plexins and transcriptional factors domain). The SEMA domain of c-Met protein may have the amino acid sequence of SEQ ID NO: 79, and is an extracellular domain that functions to bind HGF. A specific region of the SEMA domain, that is, a region including the amino acid sequence of SEQ ID NO: 71, which corresponds to a range from amino acid residues 106 to 124 of the amino acid sequence of the SEMA domain (SEQ ID NO: 79) of c-Met protein, is a loop region between the second and the third propellers within the epitopes of the SEMA domain. The region acts as an epitope for the specific anti-c-Met antibody of the present invention.

The term “epitope” as used herein, refers to an antigenic determinant, a part of an antigen recognized by an antibody. In one embodiment, the epitope may be a region including about 5 or more contiguous (consecutive or non-consecutive) amino acid residues within the SEMA domain (SEQ ID NO: 79) of c-Met protein, for instance, about 5 to about 19 contiguous amino acid residues within the amino acid sequence of SEQ ID NO: 71. For example, the epitope may be a polypeptide having about 5 to about 19 contiguous amino acids selected from among partial combinations of the amino acid sequence of SEQ ID NO: 71, wherein the polypeptide essentially includes the amino sequence of SEQ ID NO: 73 (EEPSQ) serving as an essential element for the epitope. For example, the epitope may be a polypeptide including, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

The epitope including the amino acid sequence of SEQ ID NO: 72 corresponds to the outermost part of the loop between the second and third propellers within the SEMA domain of a c-Met protein. The epitope including the amino acid sequence of SEQ ID NO: 73 is a site to which the antibody or antigen-binding fragment according to one embodiment most specifically binds.

Thus, the anti-c-Met antibody may specifically bind to an epitope which has about 5 to about 19 contiguous amino acids selected from among partial combinations of the amino acid sequence of SEQ ID NO: 71, including SEQ ID NO: 73 as an essential element. For example, the anti-c-Met antibody may specifically bind to an epitope including the amino acid sequence of SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

In one embodiment, the anti-c-Met antibody or an antigen-binding fragment thereof may comprise or consist essentially of:

at least one heavy chain complementarity determining region (CDR) selected from the group consisting of (a) a CDR-H1 including the amino acid sequence of SEQ ID NO: 4; (b) a CDR-H2 including the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 2, or an amino acid sequence having about 8-19 consecutive amino acids within SEQ ID NO: 2 including amino acid residues from the 3^(rd) to 10^(th) positions of SEQ ID NO: 2; and (c) a CDR-H3 including the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 85, or an amino acid sequence having about 6-13 consecutive amino acids within SEQ ID NO: 85 including amino acid residues from the 1^(st) to 6^(th) positions of SEQ ID NO: 85, or a heavy chain variable region including the at least one heavy chain complementarity determining region;

at least one light chain complementarity determining region (CDR) selected from the group consisting of (a) a CDR-L1 including the amino acid sequence of SEQ ID NO: 7, (b) a CDR-L2 including the amino acid sequence of SEQ ID NO: 8, and (c) a CDR-L3 including the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 86, or an amino acid sequence having 9-17 consecutive amino acids within SEQ ID NO: 89 including amino acid residues from the 1^(st) to 9^(th) positions of SEQ ID NO: 89, or a light chain variable region including the at least one light chain complementarity determining region;

a combination of the at least one heavy chain complementarity determining region and at least one light chain complementarity determining region; or

a combination of the heavy chain variable region and the light chain variable region.

Herein, the amino acid sequences of SEQ ID NOS: 4 to 9 are respectively represented by following Formulas I to VI, below:

Formula I (SEQ ID NO: 4) Xaa₁-Xaa₂-Tyr-Tyr-Met-Ser,

wherein Xaa₁ is absent or Pro or Ser, and Xaa₂ is Glu or Asp,

Formula II (SEQ ID NO: 5) Arg-Asn-Xaa₃-Xaa₄-Asn-Gly-Xaa₅-Thr,

wherein Xaa₃ is Asn or Lys, Xaa₄ is Ala or Val, and Xaa₅ is Asn or Thr,

Formula III (SEQ ID NO: 6) Asp-Asn-Trp-Leu-Xaa₆-Tyr,

wherein Xaa₆ is Ser or Thr,

Formula IV (SEQ ID NO: 7) Lys-Ser-Ser-Xaa₇-Ser-Leu-Leu-Ala-Xaa₈-Gly-Asn- Xaa₉-Xaa₁₀-Asn-Tyr-Leu-Ala

wherein Xaa₇ is His, Arg, Gln, or Lys, Xaa₈ is Ser or Trp, Xaa₉ is His or Gln, and Xaa₁₀ is Lys or Asn,

Formula V (SEQ ID NO: 8) Trp-Xaa₁₁-Ser-Xaa₁₂-Arg-Val-Xaa₁₃

wherein Xaa₁₁ is Ala or Gly, Xaa₁₂ is Thr or Lys, and Xaa₁₃ is Ser or Pro, and

Formula VI (SEQ ID NO: 9) Xaa₁₄-Gln-Ser-Tyr-Ser-Xaa₁₅-Pro-Xaa₁₆-Thr

wherein Xaa₁₄ is Gly, Ala, or Gln, Xaa₁₅ is Arg, His, Ser, Ala, Gly, or Lys, and Xaa₁₆ is Leu, Tyr, Phe, or Met.

In one embodiment, the CDR-H1 may include an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 22, 23, and 24. The CDR-H2 may include an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 25, and 26. The CDR-H3 may include an amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 27, 28, and 85.

The CDR-L1 may include an amino acid sequence selected from the group consisting of SEQ ID NOS: 10, 29, 30, 31, 32, 33, and 106. The CDR-L2 may include an amino acid sequence selected from the group consisting of SEQ ID NOS: 11, 34, 35, and 36. The CDR-L3 may include an amino acid sequence selected from the group consisting of SEQ ID NOS: 12, 13, 14, 15, 16, 37, 86, and 89.

In another embodiment, the antibody or antigen-binding fragment may include

a heavy chain variable region comprising a polypeptide (CDR-H1) including an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 22, 23, and 24, a polypeptide (CDR-H2) including an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 25, and 26, and a polypeptide (CDR-H3) including an amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 27, 28, and 85; and

a light chain variable region comprising a polypeptide (CDR-L1) including an amino acid sequence selected from the group consisting of SEQ ID NOS: 10, 29, 30, 31, 32, 33 and 106, a polypeptide (CDR-L2) including an amino acid sequence selected from the group consisting of SEQ ID NOS: 11, 34, 35, and 36, and a polypeptide (CDR-L3) including an amino acid sequence selected from the group consisting of SEQ ID NOS 12, 13, 14, 15, 16, 37, 86, and 89.

Animal-derived antibodies produced by immunizing non-immune animals with a desired antigen generally invoke immunogenicity when injected to humans for the purpose of medical treatment, and thus chimeric antibodies have been developed to inhibit such immunogenicity. Chimeric antibodies are prepared by replacing constant regions of animal-derived antibodies that cause an anti-isotype response with constant regions of human antibodies by genetic engineering. Chimeric antibodies are considerably improved in an anti-isotype response compared to animal-derived antibodies, but animal-derived amino acids still have variable regions, so that chimeric antibodies have side effects with respect to a potential anti-idiotype response. Humanized antibodies have been developed to reduce such side effects. Humanized antibodies are produced by grafting complementarity determining regions (CDR) which serve an important role in antigen binding in variable regions of chimeric antibodies into a human antibody framework.

The most important thing in CDR grafting to produce humanized antibodies is choosing the optimized human antibodies for accepting CDRs of animal-derived antibodies. Antibody databases, analysis of a crystal structure, and technology for molecule modeling are used. However, even when the CDRs of animal-derived antibodies are grafted to the most optimized human antibody framework, amino acids positioned in a framework of the animal-derived CDRs affecting antigen binding are present. Therefore, in many cases, antigen binding affinity is not maintained, and thus application of additional antibody engineering technology for recovering the antigen binding affinity is necessary.

The anti c-Met antibodies may be mouse-derived antibodies, mouse-human chimeric antibodies, humanized antibodies, or human antibodies. The antibodies or antigen-binding fragments thereof may be isolated from a living body or non-naturally occurring. The antibodies or antigen-binding fragments thereof may be synthetic or recombinant.

An intact antibody includes two full-length light chains and two full-length heavy chains, in which each light chain is linked to a heavy chain by disulfide bonds. The antibody has a heavy chain constant region and a light chain constant region. The heavy chain constant region is of a gamma (γ), mu (μ), alpha (α), delta (δ), or epsilon (ε) type, which may be further categorized as gamma 1 (γ1), gamma 2(γ2), gamma 3(γ3), gamma 4(γ4), alpha 1(α1), or alpha 2(α2). The light chain constant region is of either a kappa (κ) or lambda (λ) type.

As used herein, the term “heavy chain” refers to full-length heavy chain, and fragments thereof, including a variable region V_(H) that includes amino acid sequences sufficient to provide specificity to antigens, and three constant regions, C_(H1), C_(H2), and C_(H3), and a hinge. The term “light chain” refers to a full-length light chain and fragments thereof, including a variable region V_(L) that includes amino acid sequences sufficient to provide specificity to antigens, and a constant region C_(L).

The term “complementarity determining region (CDR)” refers to an amino acid sequence found in a hyper variable region of a heavy chain or a light chain of immunoglobulin. The heavy and light chains may respectively include three CDRs (CDRH1, CDRH2, and CDRH3; and CDRL1, CDRL2, and CDRL3). The CDR may provide contact residues that play an important role in the binding of antibodies to antigens or epitopes. The terms “specifically binding” and “specifically recognized” are well known to one of ordinary skill in the art, and indicate that an antibody and an antigen specifically interact with each other to lead to an immunological activity.

The term “hinge region,” as used herein, refers to a region between CH1 and CH2 domains within the heavy chain of an antibody which functions to provide flexibility for the antigen-binding site.

When an animal antibody undergoes a chimerization process, the IgG1 hinge of animal origin is replaced with a human IgG1 hinge or IgG2 hinge while the disulfide bridges between two heavy chains are reduced from three to two in number. In addition, an animal-derived IgG1 hinge is shorter than a human IgG1 hinge. Accordingly, the rigidity of the hinge is changed. Thus, a modification of the hinge region may bring about an improvement in the antigen binding efficiency of the humanized antibody. The modification of the hinge region through amino acid deletion, addition, or substitution is well-known to those skilled in the art.

In one embodiment, the anti-c-Met antibody or an antigen-binding fragment thereof may be modified by the deletion, insertion, addition, or substitution of at least one amino acid residue on the amino acid sequence of the hinge region so that it exhibit enhanced antigen-binding efficiency. For example, the antibody may include a hinge region including the amino acid sequence of SEQ ID NO: 100(U7-HC6), 101(U6-HC7), 102(U3-HC9), 103(U6-HC8), or 104(U8-HC5), or a hinge region including the amino acid sequence of SEQ ID NO: 105 (non-modified human hinge). In particular, the hinge region has the amino acid sequence of SEQ ID NO: 100 or 101.

In one embodiment, the anti-c-Met antibody or antigen-binding fragment may include a variable region of the heavy chain including the amino acid sequence of SEQ ID NO: 17, 74, 87, 90, 91, 92, 93, or 94, a variable region of the light chain including the amino acid sequence of SEQ ID NO: 18, 19, 20, 21, 75, 88, 95, 96, 97, 98, 99, or 107, or a combination thereof.

In one embodiment, the anti-c-Met antibody may be a monoclonal antibody. The monoclonal antibody may be produced by the hybridoma cell line deposited with Accession No. KCLRF-BP-00220, which binds specifically to the extracellular region of c-Met protein (refer to Korean Patent Publication No. 2011-0047698, the disclosure of which is incorporated in its entirety herein by reference). The anti-c-Met antibody may include all the antibodies defined in Korean Patent Publication No. 2011-0047698.

In the anti-c-Met antibody, the rest portion of the light chain and the heavy chain portion excluding the CDRs, the light chain variable region, and the heavy chain variable region as defined above, that is the light chain constant region and the heavy chain constant region, may be those from any subtype of immunoglobulin (e.g., IgA, IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4), IgM, and the like).

By way of further example, the anti-c-Met antibody or the antibody fragment may include:

a heavy chain including the amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 62 (wherein the amino acid sequence from amino acid residues from the 1^(st) to 17^(th) positions is a signal peptide), or the amino acid sequence from the 18^(th) to 462^(nd) positions of SEQ ID NO: 62, the amino acid sequence of SEQ ID NO: 64 (wherein the amino acid sequence from the 1^(st) to 17^(th) positions is a signal peptide), the amino acid sequence from the 18^(th) to 461^(st) positions of SEQ ID NO: 64, the amino acid sequence of SEQ ID NO: 66 (wherein the amino acid sequence from the 1^(st) to 17^(th) positions is a signal peptide), and the amino acid sequence from the 18^(th) to 460^(th) positions of SEQ ID NO: 66; and

a light chain including the amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 68 (wherein the amino acid sequence from the 1^(st) to 20^(th) positions is a signal peptide), the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 68, the amino acid sequence of SEQ ID NO: 70 (wherein the amino acid sequence from the 1^(st) to 20^(th) positions is a signal peptide), the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 70, and the amino acid sequence of SEQ ID NO: 108.

For example, the anti-c-Met antibody may be selected from the group consisting of:

an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 62 or the amino acid sequence from the 18^(th) to 462^(nd) positions of SEQ ID NO: 62 and a light chain including the amino acid sequence of SEQ ID NO: 68 or the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 68;

an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 64 or the amino acid sequence from the 18^(th) to 461^(st) positions of SEQ ID NO: 64 and a light chain including the amino acid sequence of SEQ ID NO: 68 or the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 68;

an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 66 or the amino acid sequence from the 18^(th) to 460^(th) positions of SEQ ID NO: 66 and a light chain including the amino acid sequence of SEQ ID NO: 68 or the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 68; an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 62 or the amino acid sequence from the 18^(th) to 462^(nd) positions of SEQ ID NO: 62 and a light chain including the amino acid sequence of SEQ ID NO: 70 or the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 70;

an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 64 or the amino acid sequence from the 18^(th) to 461^(st) positions of SEQ ID NO: 64 and a light chain including the amino acid sequence of SEQ ID NO: 70 or the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 70;

an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 66 or the amino acid sequence from the 18^(th) to 460^(th) positions of SEQ ID NO: 66 and a light chain including the amino acid sequence of SEQ ID NO: 70 or the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 70;

an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 62 or the amino acid sequence from the 18^(th) to 462^(nd) positions of SEQ ID NO: 62 and a light chain including the amino acid sequence of SEQ ID NO: 108;

an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 64 or the amino acid sequence from the 18^(th) to 461^(st) positions of SEQ ID NO: 64 and a light chain including the amino acid sequence of SEQ ID NO: 108; and

an antibody including a heavy chain including the amino acid sequence of SEQ ID NO: 66 or the amino acid sequence from the 18^(th) to 460^(th) positions of SEQ ID NO: 66 and a light chain including the amino acid sequence of SEQ ID NO: 108.

According to an embodiment, the anti-c-Met antibody may include a heavy chain including the amino acid sequence from the 18^(th) to 460^(th) positions of SEQ ID NO: 66 and a light chain including the sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 68, or a heavy chain including the amino acid sequence from the 18^(th) to 460^(th) positions of SEQ ID NO: 66 and a light chain including the sequence of SEQ ID NO: 108.

The polypeptide of SEQ ID NO: 70 is a light chain including human kappa (κ) constant region, and the polypeptide with the amino acid sequence of SEQ ID NO: 68 is a polypeptide obtained by replacing histidine at position 62 (corresponding to position 36 of SEQ ID NO: 68 according to kabat numbering) of the polypeptide with the amino acid sequence of SEQ ID NO: 70 with tyrosine. The production yield of the antibodies may be increased by the replacement. The polypeptide with the amino acid sequence of SEQ ID NO: 108 is a polypeptide obtained by replacing serine at position 32 of SEQ ID NO: 108 (corresponding to position 52 of SEQ ID NO: 68, which corresponds to position 27e according to kabat numbering in the amino acid sequence from amino acid residues 21 to 240 of SEQ ID NO: 68; positioned within CDR-L1) with tryptophan. By such replacement, antibodies and antibody fragments including such sequences exhibits increased activities, such as c-Met biding affinity, c-Met degradation activity, Akt phosphorylation inhibition, and the like.

In another embodiment, the anti-c-Met antibody may include a light chain complementarity determining region including the amino acid sequence of SEQ ID NO: 106, a light chain variable region including the amino acid sequence of SEQ ID NO: 107, or a light chain including the amino acid sequence of SEQ ID NO: 108.

The anti-c-Met/anti-EGFR bispecific antibody can not only inhibit the activity of c-Met and EGFR by the internalization and degradation activity of anti-c-Met antibody but also fundamentally block them by reducing the total amounts of c-Met and EGFR by the degradation thereof. Accordingly, the anti-c-Met/anti-EGFR bispecific antibody can obtain efficient effects even when applied to patients who have developed resistance against pre-existing anti-EGFR antibodies.

Another embodiment provides a pharmaceutical composition including the anti-EGFR antibody or an antigen-binding fragment thereof as an active ingredient. Another embodiment provides a pharmaceutical composition including the anti-c-Met/anti-EGFR bispecific antibody as an active ingredient.

In particular, another embodiment provides a pharmaceutical composition for preventing and/or treating a cancer including the anti-EGFR antibody or an antigen-binding fragment thereof as an active ingredient. Another embodiment provides a pharmaceutical composition for preventing and/or treating a cancer including the anti-c-Met/anti-EGFR bispecific antibody as an active ingredient.

Another embodiment provides a method of prevention and/or treatment a cancer, including administering a pharmaceutical effective amount of the anti-EGFR antibody or an antigen-binding fragment thereof to a patient in need of the prevention and/or treatment of the cancer. Another embodiment provides a method of prevention and/or treatment a cancer, including administering a pharmaceutical effective amount of the anti-c-Met/anti-EGFR bispecific antibody to a patient in need of the prevention and/or treatment of the cancer. The method of prevention and/or treatment a cancer may further comprises a step of identifying the patient in need of the prevention and/or treatment of the cancer, prior to the step of administering.

The cancer may be any cancer associated with overexpression and/or abnormal activation of c-Met and/or EGFR. The cancer may be any cancer in which EGFR and/or c-Met possibly plays an important role for proliferation, invasion, and metastasis, including the resistant cancers to EGFR therapy. The cancer may be a solid cancer or hematological cancer and for instance, may be, but not limited to, one or more selected from the group consisting of squamous cell carcinoma, small-cell lung cancer, non-small-cell lung cancer, adenocarcinoma of the lung, squamous cell carcinoma of the lung, peritoneal carcinoma, skin cancer, melanoma in the skin or eyeball, rectal cancer, cancer near the anus, esophagus cancer, small intestinal tumor, endocrine gland cancer, parathyroid cancer, adrenal cancer, soft-tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatoma, gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatocellular adenoma, breast cancer, colon cancer, large intestine cancer, endometrial carcinoma or uterine carcinoma, salivary gland tumor, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, head or neck cancer, brain cancer, and the like. In particular, the cancer may be cancer having resistance against pre-existing anticancer drugs, for example, antagonists against EGFR and/or antagonists against c-Met. The prevention and/or treatment effects of the cancers may include effects of not only suppressing the growth of the cancer cells but also suppressing deterioration of cancers due to migration, invasion, and/or metastasis thereof. Therefore, the curable cancers may include both primary cancers and metastatic cancers. Thus, the pharmaceutical composition or method may be for preventing and/or treating cancer metastasis.

In the pharmaceutical composition or method, the pharmaceutically effective amount of the anti-EGFR antibody or an antigen-binding fragment thereof or the anti-c-Met/anti-EGFR bispecific antibody may be administered along with at least one additive selected from the group consisting of a pharmaceutically acceptable carriers, diluents, and excipients.

The pharmaceutically acceptable carrier to be included in the composition may be those commonly used for the formulation of antibodies, which may be one or more selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginates, gelatin, calcium silicate, micro-crystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oil, but are not limited thereto. The pharmaceutical composition may further include one or more selected from the group consisting of a lubricant, a wetting agent, a sweetener, a flavor enhancer, an emulsifying agent, a suspension agent, and preservative.

The pharmaceutical composition or the anti-EGFR antibody or an antigen-binding fragment thereof or the anti-c-Met/anti-EGFR bispecific antibody may be administered orally or parenterally. The parenteral administration may include intravenous injection, subcutaneous injection, muscular injection, intraperitoneal injection, endothelial administration, local administration, intranasal administration, intrapulmonary administration, and rectal administration. Since oral administration leads to digestion of proteins or peptides, an active ingredient in the compositions for oral administration must be coated or formulated to prevent digestion in stomach. In addition, the compositions may be administered using an optional device that enables an active substance to be delivered to target cells.

A suitable dosage of the pharmaceutical composition, the anti-EGFR antibody or an antigen-binding fragment thereof, or the anti-c-Met/anti-EGFR bispecific antibody may be prescribed in a variety of ways, depending on factors such as formulation methods, administration methods, age of patients, body weight, gender, pathologic conditions, diets, administration time, administration route, excretion speed, and reaction sensitivity. A desirable dosage of the pharmaceutical composition or the anti-c-Met/anti-EGFR bispecific antibody may be in the range of about 0.001 to 100 mg/kg for an adult. For example, the suitable dosage of the pharmaceutical composition, the anti-EGFR antibody or an antigen-binding fragment thereof, or the anti-c-Met/anti-EGFR bispecific antibody may be about 0.001 to about 1000 mg/kg, about 0.01 to about 100 mg/kg, or 0.1 to 50 mg/kg, per a day, but not be limited thereto. The term “pharmaceutically effective amount” used herein refers to an amount of the active ingredient (i.e., the anti-EGFR antibody or an antigen-binding fragment thereof, or the anti-c-Met/anti-EGFR bispecific antibody) exhibiting effects in preventing or treating cancer, and may be properly determined in a variety of ways, depending on factors such as formulation methods, administration methods, age of patients, body weight, gender, pathologic conditions, diets, administration time, administration route, excretion speed, and reaction sensitivity.

The pharmaceutical composition or the anti-c-Met/anti-EGFR bispecific antibody may be formulated with a pharmaceutically acceptable carrier and/or excipient into a unit or a multiple dosage form by a method easily carried out by a skilled person in the pertinent art. The dosage form may be a solution in oil or an aqueous medium, a suspension, syrup, an emulsifying solution, an extract, powder, granules, a tablet, or a capsule, and may further include a dispersing or a stabilizing agent.

In addition, the pharmaceutical composition or the anti-c-Met/anti-EGFR bispecific antibody may be administered as an individual drug, or together with other drugs, and may be administered sequentially or simultaneously with pre-existing drugs.

Since the pharmaceutical composition includes an antibody or an antigen binding fragment thereof, it may be formulated as an immunoliposome. The liposome containing an antibody may be prepared using a well-known method in the pertinent art. The immunoliposome is a lipid composition including phosphatidylcholine, cholesterol, and polyethyleneglycol-derivatized phosphatidylethanolamine, and may be prepared by a reverse phase evaporation method. For example, Fab′ fragments of an antibody may be conjugated to the liposome through a disulfide exchange reaction. A chemical drug such as doxorubicin may be additionally included in the liposome.

The subject to which the pharmaceutical composition is administered or the patient to which the prevention and/treatment method is applied may be mammals, for example, primates such as humans and monkeys, or rodents such as rats and mice, but are not be limited thereto. The subject or the patient may be a cancer patient having resistance against pre-existing anticancer drugs, for example, antagonists against the target cell membrane proteins (e.g., EGFR).

Another embodiment provides a polynucleotide encoding a polypeptide including one amino acid sequence or a combination of two or more amino acid sequences selected from the group consisting of SEQ ID NO: 109 to SEQ ID NO: 114. In a particular embodiment, the polynucleotide may encode a polypeptide including the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, a polypeptide including the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, or a combination thereof. Another embodiment provides a recombinant vector including the polynucleotide. Another embodiment provides a recombinant cell transfected with the recombinant vector.

The term “vector” used herein refers to a means for expressing a target gene in a host cell. For example, it includes a plasmid vector, a cosmid vector, and a virus vector such as a bacteriophage vector, an adenovirus vector, a retrovirus vector and an adeno-associated virus vector. Suitable recombinant vectors may be constructed by manipulating plasmids often used in the art (for example, pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series, pUC19, and the like), a phage (for example, λgt4λB, λ-Charon, λΔz1, M13, and the like), or a virus (for example, SV40, and the like), but not be limited thereto.

In the recombinant vector, the polynucleotides may be operatively linked to a promoter. The term “operatively linked” used herein refers to a functional linkage between a nucleotide expression regulating sequence (for example, a promoter sequence) and other nucleotide sequences. Thus, the regulating sequence may regulate the transcription and/or translation of the other nucleotide sequences by being operatively linked.

The recombinant vector may be constructed for cloning or expression. The expression vector may be any ordinary vectors known in the pertinent art for expressing an exogenous protein in plants, animals, or microorganisms. The recombinant vector may be constructed using various methods known in the art.

The recombinant vector may be constructed using a prokaryotic cell or a eukaryotic cell as a host. For example, when a prokaryotic cell is used as a host cell, the expression vector used generally includes a strong promoter capable of initiating transcription (for example, pL^(λ) promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter, and the like), a ribosome binding site for initiating translation, and a transcription/translation termination sequence. When a eukaryotic cell is used as a host cell, the vector used generally includes the origin of replication acting in the eukaryotic cell, for example, an f1 replication origin, a SV40 replication origin, a pMB1 replication origin, an adeno replication origin, an AAV replication origin, or a BBV replication origin, but is not limited thereto. A promoter in an expression vector for a eukaryotic host cell may be a promoter derived from the genomes of mammalian cells (for example, a metallothionein promoter, and the like) or a promoter derived from mammalian viruses (for example, an adenovirus late promoter, a vaccinia virus 7.5K promoter, a SV40 promoter, a cytomegalovirus promoter, a tk promoter of HSV, and the like). A transcription termination sequence in an expression vector for a eukaryotic host cell may be, in general, a polyadenylation sequence.

The recombinant cell may be those obtained by transfecting the recombinant vector into a suitable host cell. Any host cells known in the pertinent art to enable stable and continuous cloning or expression of the recombinant vector may be used as the hose cell. Suitable prokaryotic host cells may be one or more selected from E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. coli B, E. coli X 1776, E. coli W3110, Bacillus species strains such as Bacillus subtillis, or Bacillus thuringiensis, intestinal bacteria and strains such as Salmonella typhymurum, Serratia marcescens, and various Pseudomonas species. Suitable eukaryotic host cells to be transformed may be one or more selected from yeasts, such as Saccharomyces cerevisiae, insect cells, plant cells, and animal cells, for example, Sp2/0, Chinese hamster ovary (CHO) K1, CHO DG44, PER.C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN, and MDCK cell lines, but not be limited thereto.

The polynucleotide or the recombinant vector including the same may be transferred (transfected) into a host cell by using known transfer methods. Suitable transfer methods for prokaryotic host cells may include a method using CaCl₂ and electroporation. Suitable transfer methods for eukaryotic host cells may include microinjection, calcium phosphate precipitation, electroporation, liposome-mediated transfection, and gene bombardment, but are not limited thereto.

A transformed host cell may be selected using a phenotype expressed by a selected marker by any methods known in the art. For example, if the selected marker is a gene that is resistant to a specific antibiotic, a transformant may be easily selected by being cultured in a medium including the antibiotic.

The anti-c-Met/anti-EGFR bispecific antibody may be expected to exhibit an improved effect compared to a previously known anti-c-Met antibody, as follows:

1. an increased cancer cell inhibition effect compared to pre-existing anti-c-Met antibodies or EGFR-targeting drugs.

2. a cancer cell inhibition effect on a cancer cells having resistance to pre-existing anti-c-Met antibodies or EGFR-targeting drugs.

Hereafter, the present invention will be described in detail by examples.

The following examples are intended merely to illustrate the invention and are not construed to restrict the invention.

EXAMPLES Reference Example 1 Construction of Anti-c-Met Antibody

1.1. Production of “AbF46”, a Mouse Antibody to c-Met

1.1.1. Immunization of Mouse

To obtain immunized mice necessary for the development of a hybridoma cell line, each of five BALB/c mice (Japan SLC, Inc.), 4 to 6 weeks old, was intraperitoneally injected with a mixture of 100 μg of human c-Met/Fc fusion protein (R&D Systems) and one volume of complete Freund's adjuvant. Two weeks after the injection, a second intraperitoneal injection was conducted on the same mice with a mixture of 50 μg of human c-Met/Fc protein and one volume of incomplete Freund's adjuvant. One week after the second immunization, the immune response was finally boosted. Three days later, blood was taken from the tails of the mice and the sera were 1/1000 diluted in PBS and used to examine a titer of antibody to c-Met by ELISA. Mice found to have a sufficient antibody titer were selected for use in the cell fusion process.

1.1.2. Cell Fusion and Production of Hybridoma

Three days before cell fusion, BALB/c mice (Japan SLC, Inc.) were immunized with an intraperitoneal injection of a mixture of 50 μg of human c-Met/Fc fusion protein and one volume of PBS. The immunized mice were anesthetized before excising the spleen from the left half of the body. The spleen was meshed to separate splenocytes which were then suspended in a culture medium (DMEM, GIBCO, Invitrogen). The cell suspension was centrifuged to recover the cell layer. The splenocytes thus obtained (1×10⁸ cells) were mixed with myeloma cells (Sp2/0) (1×10⁸ cells), followed by spinning to give a cell pellet. The cell pellet was slowly suspended, treated with 45% polyethylene glycol (PEG) (1 mL) in DMEM for 1 min at 37° C., and supplemented with 1 mL of DMEM. To the cells was added 10 mL of DMEM over 10 min, after which incubation was conducted in a water bath at 37° C. for 5 min. Then the cell volume was adjusted to 50 mL before centrifugation. The cell pellet thus formed was resuspended at a density of 1-2×10⁵ cells/mL in a selection medium (HAT medium) and 0.1 mL of the cell suspension was allocated to each well of 96-well plates which were then incubated at 37° C. in a CO₂ incubator to establish a hybridoma cell population.

1.1.3. Selection of Hybridoma Cells Producing Monoclonal Antibodies to c-Met Protein

From the hybridoma cell population established in Reference Example 1.1.2, hybridoma cells which showed a specific response to c-Met protein were screened by ELISA using human c-Met/Fc fusion protein and human Fc protein as antigens.

Human c-Met/Fc fusion protein was seeded in an amount of 50 μL (2 μg/mL)/well to microtiter plates and allowed to adhere to the surface of each well. The antibody that remained unbound was removed by washing. For use in selecting the antibodies that do not bind c-Met but recognize Fc, human Fc protein was attached to the plate surface in the same manner.

The hybridoma cell culture obtained in Reference Example 1.1.2 was added in an amount of 50 μL to each well of the plates and incubated for 1 hour. The cells remaining unreacted were washed out with a sufficient amount of Tris-buffered saline and Tween 20 (TBST). Goat anti-mouse IgG-horseradish peroxidase (HRP) was added to the plates and incubated for 1 hour at room temperature. The plates were washed with a sufficient amount of TBST, followed by reacting the peroxidase with a substrate (OPD). Absorbance at 450 nm was measured on an ELISA reader.

Hybridoma cell lines which secrete antibodies that specifically and strongly bind to human c-Met but not human Fc were selected repeatedly. From the hybridoma cell lines obtained by repeated selection, a single clone producing a monoclonal antibody was finally separated by limiting dilution. The single clone of the hybridoma cell line producing the monoclonal antibody was deposited with the Korean Cell Line Research Foundation, an international depository authority located at Yungun-Dong, Jongno-Gu, Seoul, Korea, on Oct. 6, 2009, with Accession No. KCLRF-BP-00220 according to the Budapest Treaty (refer to Korean Patent Laid-Open Publication No. 2011-0047698).

1.1.4. Production and Purification of Monoclonal Antibody

The hybridoma cell line obtained in Reference Example 1.1.3 was cultured in a serum-free medium, and the monoclonal antibody (AbF46) was produced and purified from the cell culture.

First, the hybridoma cells cultured in 50 mL of a medium (DMEM) supplemented with 10% (v/v) FBS were centrifuged and the cell pellet was washed twice or more with 20 mL of PBS to remove the FBS therefrom. Then, the cells were resuspended in 50 mL of DMEM and incubated for 3 days at 37° C. in a CO₂ incubator.

After the cells were removed by centrifugation, the supernatant was stored at 4° C. before use or immediately used for the separation and purification of the antibody. An AKTA system (GE Healthcare) equipped with an affinity column (Protein G agarose column; Pharmacia, USA) was used to purify the antibody from 50 to 300 mL of the supernatant, followed by concentration with an filter (Amicon). The antibody in PBS was stored before use in the following examples.

1.2. Construction of chAbF46, a Chimeric Antibody to c-Met

A mouse antibody is apt to elicit immunogenicity in humans. To solve this problem, chAbF46, a chimeric antibody, was constructed from the mouse antibody AbF46 produced in Experimental Example 1.1.4 by replacing the constant region, but not the variable region responsible for antibody specificity, with an amino sequence of the human IgG1 antibody.

In this regard, a gene was designed to include the nucleotide sequence of “EcoRI-signal sequence-VH-NheI-CH-TGA-XhoI” (SEQ ID NO: 38) for a heavy chain and the nucleotide sequence of “EcoRI-signal sequence-VL-BsiWI-CL-TGA-XhoI” (SEQ ID NO: 39) for a light chain and synthesized. Then, a DNA fragment having the heavy chain nucleotide sequence (SEQ ID NO: 38) and a DNA fragment having the light chain nucleotide sequence (SEQ ID NO: 39) were digested with EcoRI (NEB, R0101S) and XhoI (NEB, R0146S) before cloning into a pOptiVEC™-TOPO TA Cloning Kit enclosed in an OptiCHO™ Antibody Express Kit (Cat no. 12762-019, Invitrogen), and a pcDNA™3.3-TOPO TA Cloning Kit (Cat no. 8300-01), respectively.

Each of the constructed vectors was amplified using Qiagen Maxiprep kit (Cat no. 12662), and a transient expression was performed using Freestyle™ MAX 293 Expression System (invitrogen). 293 F cells were used for the expression and cultured in FreeStyle™ 293 Expression Medium in a suspension culture manner. At one day before the transient expression, the cells were provided in the concentration of 5×10⁵ cells/ml, and after 24 hours, when the cell number reached to 1×10⁶ cells/ml, the transient expression was performed. A transfection was performed by a liposomal reagent method using Freestyle™ MAX reagent (invitrogen), wherein in a 15 ml tube, the DNA was provided in the mixture ratio of 1:1 (heavy chain DNA: light chain DNA) and mixed with 2 ml of OptiPro™ SFM (Invtrogen) (A), and in another 15 ml tube, 100 ul (microliter) of Freestyle™ MAX reagent and 2 ml of OptiPro™ SFM were mixed (B), followed by mixing (A) and (B) and incubating for 15 minutes. The obtained mixture was slowly mixed with the cells provided one day before the transient expression. After completing the transfection, the cells were incubated in 130 rpm incubator for 5 days under the conditions of 37° C., 80% humidity, and 8% CO₂.

Afterwards, the cells were incubated in DMEM supplemented with 10% (v/v) FBS for 5 hours at 37° C. under a 5% CO₂ condition and then in FBS-free DMEM for 48 hours at 37° C. under a 5% CO₂ condition.

After centrifugation, the supernatant was applied to AKTA prime (GE Healthcare) to purify the antibody. In this regard, 100 mL of the supernatant was loaded at a flow rate of 5 mL/min to AKTA Prime equipped with a Protein A column (GE healthcare, 17-0405-03), followed by elution with an IgG elution buffer (Thermo Scientific, 21004). The buffer was exchanged with PBS to purify a chimeric antibody AbF46 (hereinafter referred to as “chAbF46”).

1.3. Construction of Humanized Antibody huAbF46 from Chimeric Antibody chAbF46

1.3.1. Heavy Chain Humanization

To design two domains H1-heavy and H3-heavy, human germline genes which share the highest identity/homology with the VH gene of the mouse antibody AbF46 purified in Reference Example 1.2 were analyzed. An Ig BLAST (www.ncbi.nlm.nih.gov/igblast/) result revealed that VH3-71 has an identity/identity/homology of 83% at the amino acid level. CDR-H1, CDR-H2, and CDR-H3 of the mouse antibody AbF46 were defined according to Kabat numbering. A design was made to introduce the CDR of the mouse antibody AbF46 into the framework of VH3-71. Back mutations to the amino acid sequence of the mouse AbF46 were conducted at positions 30 (S→T), 48 (V→L), 73 (D→N), and 78 (T→L). Then, H1 was further mutated at positions 83 (R→K) and 84 (A→T) to finally establish H1-heavy (SEQ ID NO: 40) and H3-heavy (SEQ ID NO: 41).

For use in designing H4-heavy, human antibody frameworks were analyzed by a BLAST search. The result revealed that the VH3 subtype, known to be most stable, is very similar in framework and sequence to the mouse antibody AbF46. CDR-H1, CDR-H2, and CDR-H3 of the mouse antibody AbF46 were defined according to Kabat numbering and introduced into the VH3 subtype to construct H4-heavy (SEQ ID NO: 42).

1.3.2. Light Chain Humanization

To design two domains H1-light (SEQ ID NO: 43) and H2-light (SEQ ID NO: 44), human germline genes which share the highest identity/homology with the VH gene of the mouse antibody AbF46 were analyzed. An Ig BLAST search result revealed that VK4-1 has a identity/homology of 75% at the amino acid level. CDR-L1, CDR-L2, and CDR-L3 of the mouse antibody AbF46 were defined according to Kabat numbering. A design was made to introduce the CDR of the mouse antibody AbF46 into the framework of VK4-1. Back mutations to the amino acid sequence of the mouse AbF46 were conducted at positions 36 (Y→H), 46 (L→M), and 49 (Y→I). Only one back mutation was conducted at position 49 (Y→I) on H2-light.

To design H3-light (SEQ ID NO: 45), human germline genes which share the highest identity/homology with the VL gene of the mouse antibody AbF46 were analyzed by a search for BLAST. As a result, VK2-40 was selected. VL and VK2-40 of the mouse antibody AbF46 were found to have a identity/homology of 61% at an amino acid level. CDR-L1, CDR-L2, and CDR-L3 of the mouse antibody were defined according to Kabat numbering and introduced into the framework of VK4-1. Back mutations were conducted at positions 36 (Y→H), 46 (L→M), and 49 (Y→I) on H3-light.

For use in designing H4-light (SEQ ID NO: 46), human antibody frameworks were analyzed. A Blast search revealed that the Vk1 subtype, known to be the most stable, is very similar in framework and sequence to the mouse antibody AbF46. CDR-L1, CDR-L2, and CDR-L3 of the mouse antibody AbF46 were defined according to Kabat numbering and introduced into the Vk1 subtype. Back mutations were conducted at positions 36 (Y→H), 46 (L→M), and 49 (Y→I) on H4-light.

Thereafter, DNA fragments having the heavy chain nucleotide sequences (H1-heavy: SEQ ID NO: 47, H3-heavy: SEQ ID NO: 48, H4-heavy: SEQ ID NO: 49) and DNA fragments having the light chain nucleotide sequences (H1-light: SEQ ID NO: 50, H2-light: SEQ ID NO: 51, H3-light: SEQ ID NO: 52, H4-light: SEQ ID NO: 53) were digested with EcoRI (NEB, R0101S) and XhoI (NEB, R0146S) before cloning into a pOptiVEC™-TOPO TA Cloning Kit enclosed in an OptiCHO™ Antibody Express Kit (Cat no. 12762-019, Invitrogen) and a pcDNA™3.3-TOPO TA Cloning Kit (Cat no. 8300-01), respectively, so as to construct recombinant vectors for expressing a humanized antibody.

Each of the constructed vectors was amplified using Qiagen Maxiprep kit (Cat no. 12662), and a transient expression was performed using Freestyle™ MAX 293 Expression System (invitrogen). 293 F cells were used for the expression and cultured in FreeStyle™ 293 Expression Medium in a suspension culture manner. At one day before the transient expression, the cells were provided in the concentration of 5×10⁵ cells/ml, and after 24 hours, when the cell number reached to 1×10⁶ cells/ml, the transient expression was performed. A transfection was performed by a liposomal reagent method using Freestyle™ MAX reagent (invitrogen), wherein in a 15 ml tube, the DNA was provided in the mixture ratio of 1:1 (heavy chain DNA: light chain DNA) and mixed with 2 ml of OptiPro™ SFM (invtrogen) (A), and in another 15 ml tube, 100 ul (microliter) of Freestyle™ MAX reagent and 2 ml of OptiPro™ SFM were mixed (B), followed by mixing (A) and (B) and incubating for 15 minutes. The obtained mixture was slowly mixed with the cells provided one day before the transient expression. After completing the transfection, the cells were incubated in 130 rpm incubator for 5 days under the conditions of 37° C., 80% humidity, and 8% CO₂.

After centrifugation, the supernatant was applied to AKTA prime (GE Healthcare) to purify the antibody. In this regard, 100 mL of the supernatant was loaded at a flow rate of 5 mL/min to AKTA Prime equipped with a Protein A column (GE healthcare, 17-0405-03), followed by elution with an IgG elution buffer (Thermo Scientific, 21004). The buffer was exchanged with PBS to purify a humanized antibody AbF46 (hereinafter referred to as “huAbF46”). The humanized antibody huAbF46 used in the following examples included a combination of H4-heavy (SEQ ID NO: 42) and H4-light (SEQ ID NO: 46).

1.4. Construction of scFv Library of huAbF46 Antibody

For use in constructing an scFv of the huAbF46 antibody from the heavy and light chain variable regions of the huAbF46 antibody, a gene was designed to have the structure of “VH-linker-VL” for each of the heavy and the light chain variable region, with the linker including the amino acid sequence “GLGGLGGGGSGGGGSGGSSGVGS” (SEQ ID NO: 54). A polynucleotide sequence (SEQ ID NO: 55) encoding the designed scFv of huAbF46 was synthesized in Bioneer and an expression vector for the polynucleotide had the nucleotide sequence of SEQ ID NO: 56.

After expression, the product was found to exhibit specificity to c-Met.

1.5. Construction of Library Genes for Affinity Maturation

1.5.1. Selection of Target CDRs and Synthesis of Primers

The affinity maturation of huAbF46 was achieved. First, six complementary determining regions (CDRs) were defined according to Kabat numbering. The CDRs are given in Table 2, below.

TABLE 2 CDR Amino Acid Sequence CDR-H1 DYYMS (SEQ ID NO: 1) CDR-H2 FIRNKANGYTTEYSASVKG(SEQ ID NO: 2) CDR-H3 DNWFAY (SEQ ID NO: 3) CDR-L1 KSSQSLLASGNQNNYLA (SEQ ID NO: 10) CDR-L2 WASTRVS (SEQ ID NO: 11) CDR-L3 QQSYSAPLT (SEQ ID NO: 12)

For use in the introduction of random sequences into the CDRs of the antibody, primers were designed as follows. Conventionally, N codons were utilized to introduce bases at the same ratio (25% A, 25% G, 25% C, 25% T) into desired sites of mutation. In this experiment, the introduction of random bases into the CDRs of huAbF46 was conducted in such a manner that, of the three nucleotides per codon in the wild-type polynucleotide encoding each CDR, the first and second nucleotides conserved over 85% of the entire sequence while the other three nucleotides were introduced at the same percentage (each 5%) and that the same possibility was imparted to the third nucleotide (33% G, 33% C, 33% T).

1.5.2. Construction of a Library of huAbF46 Antibodies and Affinity for c-Met

The construction of antibody gene libraries through the introduction of random sequences was carried out using the primers synthesized in the same manner as in Reference Example 1.5.1. Two PCR products were obtained using a polynucleotide covering the scFV of huAbF46 as a template, and were subjected to overlap extension PCR to give scFv library genes for huAbF46 antibodies in which only desired CDRs were mutated. Libraries targeting each of the six CDRs prepared from the scFV library genes were constructed.

The affinity for c-Met of each library was compared to that of the wildtype. Most libraries were lower in affinity for c-Met, compared to the wild-type. The affinity for c-Met was retained in some mutants.

1.6. Selection of Antibody with Improved Affinity from Libraries

After maturation of the affinity of the constructed libraries for c-Met, the nucleotide sequence of scFv from each clone was analyzed. The nucleotide sequences thus obtained are summarized in Table 3 and were converted into IgG forms. Four antibodies which were respectively produced from clones L3-1, L3-2, L3-3, and L3-5 were used in the subsequent experiments.

TABLE 3 Library Clone onstructed CDR Sequence H11-4 CDR-H1 PEYYMS (SEQ ID NO: 22) YC151 CDR-H1 PDYYMS (SEQ ID NO: 23) YC193 CDR-H1 SDYYMS (SEQ ID NO: 24) YC244 CDR-H2 RNNANGNT (SEQ ID NO: 25) YC321 CDR-H2 RNKVNGYT (SEQ ID NO: 26) YC354 CDR-H3 DNWLSY (SEQ ID NO: 27) YC374 CDR-H3 DNWLTY (SEQ ID NO: 28) L1-1 CDR-L1 KSSHSLLASGNQNNYLA (SEQ ID NO: 29) L1-3 CDR-L1 KSSRSLLSSGNHKNYLA (SEQ ID NO: 30) L1-4 CDR-L1 KSSKSLLASGNQNNYLA (SEQ ID NO: 31) L1-12 CDR-L1 KSSRSLLASGNQNNYLA (SEQ ID NO: 32) L1-22 CDR-L1 KSSHSLLASGNQNNYLA (SEQ ID NO: 33) L2-9 CDR-L2 WASKRVS (SEQ ID NO: 34) L2-12 CDR-L2 WGSTRVS (SEQ ID NO: 35) L2-16 CDR-L2 WGSTRVP (SEQ ID NO: 36) L3-1 CDR-L3 QQSYSRPYT (SEQ ID NO: 13) L3-2 CDR-L3 GQSYSRPLT (SEQ ID NO: 14) L3-3 CDR-L3 AQSYSHPFS (SEQ ID NO: 15) L3-5 CDR-L3 QQSYSRPFT (SEQ ID NO: 16) L3-32 CDR-L3 QQSYSKPFT (SEQ ID NO: 37)

1.7. Conversion of Selected Antibodies into IgG

Respective polynucleotides encoding heavy chains of the four selected antibodies were designed to have the structure of “EcoRI-signal sequence-VH-NheI—CH-XhoI” (SEQ ID NO: 38). The heavy chains of huAbF46 antibodies were used as they were because their amino acids were not changed during affinity maturation. In the case of the hinge region, however, the U6-HC7 hinge (SEQ ID NO: 57) was employed instead of the hinge of human IgG1. Genes were also designed to have the structure of “EcoRI-signal sequence-VL-BsiWI-CL-XhoI” for the light chain. Polypeptides encoding light chain variable regions of the four antibodies which were selected after the affinity maturation were synthesized in Bioneer. Then, a DNA fragment having the heavy chain nucleotide sequence (SEQ ID NO: 38) and DNA fragments having the light chain nucleotide sequences (DNA fragment including L3-1-derived CDR-L3: SEQ ID NO: 58, DNA fragment including L3-2-derived CDR-L3: SEQ ID NO: 59, DNA fragment including L3-3-derived CDR-L3: SEQ ID NO: 60, and DNA fragment including L3-5-derived CDR-L3: SEQ ID NO: 61) were digested with EcoRI (NEB, R0101S) and XhoI (NEB, R0146S) before cloning into a pOptiVEC™-TOPO TA Cloning Kit enclosed in an OptiCHO™ Antibody Express Kit (Cat no. 12762-019, Invitrogen) and a pcDNA™3.3-TOPO TA Cloning Kit (Cat no. 8300-01), respectively, so as to construct recombinant vectors for expressing affinity-matured antibodies.

Each of the constructed vectors was amplified using Qiagen Maxiprep kit (Cat no. 12662), and a transient expression was performed using Freestyle™ MAX 293 Expression System (invitrogen). 293 F cells were used for the expression and cultured in FreeStyle™ 293 Expression Medium in a suspension culture manner. At one day before the transient expression, the cells were provided in the concentration of 5×10⁵ cells/ml, and after 24 hours, when the cell number reached to 1×10⁶ cells/ml, the transient expression was performed. A transfection was performed by a liposomal reagent method using Freestyle™ MAX reagent (invitrogen), wherein in a 15 ml tube, the DNA was provided in the mixture ratio of 1:1 (heavy chain DNA: light chain DNA) and mixed with 2 ml of OptiPro™ SFM (invtrogen) (A), and in another 15 ml tube, 100 ul (microliter) of Freestyle™ MAX reagent and 2 ml of OptiPro™ SFM were mixed (B), followed by mixing (A) and (B) and incubating for 15 minutes. The obtained mixture was slowly mixed with the cells provided one day before the transient expression. After completing the transfection, the cells were incubated in 130 rpm incubator for 5 days under the conditions of 37° C., 80% humidity, and 8% CO₂.

After centrifugation, the supernatant was applied to AKTA prime (GE Healthcare) to purify the antibody. In this regard, 100 mL of the supernatant was loaded at a flow rate of 5 mL/min to AKTA Prime equipped with a Protein A column (GE healthcare, 17-0405-03), followed by elution with an IgG elution buffer (Thermo Scientific, 21004). The buffer was exchanged with PBS to purify four affinity-matured antibodies (hereinafter referred to as “huAbF46-H4-A1 (L3-1 origin), huAbF46-H4-A2 (L3-2 origin), huAbF46-H4-A3 (L3-3 origin), and huAbF46-H4-A5 (L3-5 origin),” respectively).

1.8. Construction of Constant Region- and/or Hinge Region-Substituted huAbF46-H4-A1

Among the four antibodies selected in Reference Example 1.7, huAbF46-H4-A1 was found to be the highest in affinity for c-Met and the lowest in Akt phosphorylation and c-Met degradation degree. In the antibody, the hinge region, or the constant region and the hinge region, were substituted.

The antibody huAbF46-H4-A1 (U6-HC7) was composed of a heavy chain including the heavy chain variable region of huAbF46-H4-A1, U6-HC7 hinge, and the constant region of human IgG1 constant region, and a light chain including the light chain variable region of huAbF46-H4-A1 and human kappa constant region. The antibody huAbF46-H4-A1 (IgG2 hinge) was composed of a heavy chain including a heavy chain variable region, a human IgG2 hinge region, and a human IgG1 constant region, and a light chain including the light chain variable region of huAbF46-H4-A1 and a human kappa constant region. The antibody huAbF46-H4-A1 (IgG2 Fc) was composed of the heavy chain variable region of huAbF46-H4-A1, a human IgG2 hinge region, and a human IgG2 constant region, and a light chain including the light variable region of huAbF46-H4-A1 and a human kappa constant region. The histidine residue at position 36 on the human kappa constant region of the light chain was changed to tyrosine in all of the three antibodies to increase antibody production.

For use in constructing the three antibodies, a polynucleotide (SEQ ID NO: 63) encoding a polypeptide (SEQ ID NO: 62) composed of the heavy chain variable region of huAbF46-H4-A1, a U6-HC7 hinge region, and a human IgG1 constant region, a polynucleotide (SEQ ID NO: 65) encoding a polypeptide (SEQ ID NO: 64) composed of the heavy chain variable region of huAbF46-H4-A1, a human IgG2 hinge region, and a human IgG1 region, a polynucleotide (SEQ ID NO: 67) encoding a polypeptide (SEQ ID NO: 66) composed of the heavy chain variable region of huAbF46-H4-A1, a human IgG2 region, and a human IgG2 constant region, and a polynucleotide (SEQ ID NO: 69) encoding a polypeptide (SEQ ID NO: 68) composed of the light chain variable region of huAbF46-H4-A1, with a tyrosine residue instead of histidine at position 36, and a human kappa constant region were synthesized in Bioneer. Then, the DNA fragments having heavy chain nucleotide sequences were inserted into a pOptiVEC™-TOPO TA Cloning Kit enclosed in an OptiCHO™ Antibody Express Kit (Cat no. 12762-019, Invitrogen) while DNA fragments having light chain nucleotide sequences were inserted into a pcDNA™3.3-TOPO TA Cloning Kit (Cat no. 8300-01) so as to construct vectors for expressing the antibodies.

Each of the constructed vectors was amplified using Qiagen Maxiprep kit (Cat no. 12662), and a transient expression was performed using Freestyle™ MAX 293 Expression System (invitrogen). 293 F cells were used for the expression and cultured in FreeStyle™ 293 Expression Medium in a suspension culture manner. At one day before the transient expression, the cells were provided in the concentration of 5×10⁵ cells/ml, and after 24 hours, when the cell number reached to 1×10⁶ cells/ml, the transient expression was performed. A transfection was performed by a liposomal reagent method using Freestyle™ MAX reagent (invitrogen), wherein in a 15 ml tube, the DNA was provided in the mixture ratio of 1:1 (heavy chain DNA:light chain DNA) and mixed with 2 ml of OptiPro™ SFM (invtrogen) (A), and in another 15 ml tube, 100 ul (microliter) of Freestyle™ MAX reagent and 2 ml of OptiPro™ SFM were mixed (B), followed by mixing (A) and (B) and incubating for 15 minutes. The obtained mixture was slowly mixed with the cells provided one day before the transient expression. After completing the transfection, the cells were incubated in 130 rpm incubator for 5 days under the conditions of 37° C., 80% humidity, and 8% CO₂.

After centrifugation, the supernatant was applied to AKTA prime (GE Healthcare) to purify the antibody. In this regard, 100 mL of the supernatant was loaded at a flow rate of 5 mL/min to AKTA Prime equipped with a Protein A column (GE healthcare, 17-0405-03), followed by elution with IgG elution buffer (Thermo Scientific, 21004). The buffer was exchanged with PBS to finally purify three antibodies (huAbF46-H4-A1 (U6-HC7), huAbF46-H4-A1 (IgG2 hinge), and huAbF46-H4-A1 (IgG2 Fc)). Among the three antibodies, huAbF46-H4-A1 (IgG2 Fc) was selected for the following examples, and name as L3-1Y-IgG2.

Example 1 Preparation of Anti-EGFR scFv

An anti-EGFR scFv binding to EGFR was prepared by inserting a peptide linker of (GGGGS)₃ between a heavy chain variable region of SEQ ID NO: 115 and a light chain variable region of SEQ ID NO: 116. In particular, the DNA sequence encoding a (GGGGS)₃ linker peptide was added to the DNA sequence (SEQ ID NO: 119) encoding the heavy chain variable region (SEQ ID NO: 115) and the DNA sequence (SEQ ID NO: 120) encoding the light chain variable region (SEQ ID NO: 116) of a humanized anti-EGFR antibody using an automatic gene synthesis (Bioneer Inc.) to synthesize a DNA fragment encoding a scFv of the anti-EGFR antibody. An anti-EGFR scFv prepared from the synthesized DNA fragment was named as “anti-EGFR antibody E-2”.

The amino acid sequences of the heavy chain variable region and the light chain variable region of the prepared anti-EGFR scFv, and coding nucleotide sequences thereof are summarized in Table 4, as follows (wherein the sequences marked in bold type indicate CDRs, i.e., CDR-H1, CDR-H2, and CDR-H3, or CDR-L1, CDR-L2, and CDR-L3, in sequence):

TABLE 4 Heavy chain variable region of Light chain variable region of anti-EGFR antibody E-2 anti-EGFR antibody E-2 Amino EVQLLESGGGLVQPGGSLRL QSVLTQPPSASGTPGQRVTISC acid SCAASGFTFSNYDMSWVRQ TGSSSNIGNNDVSWYQQLPG sequence APGKGLEWVSGISHSSGSKY TAPKLLIYDDNKRPSGVPDRF YADSVKGRFTISRDNSKNTL SGSKSGTSASLAISGLRSEDEA YLQMNSLRAEDTAVYYCAK DYYCGSWDASLNAYVFGGG DATPRPLKPFDYWGQGTLV TKLTVLG (SEQ ID NO: 116) TVSS (SEQ ID NO: 115) Coding GAGGTGCAGCTGTTGGAGT CAGTCTGTGCTGACTCAGCC nucleotide CTGGGGGAGGCTTGGTACA ACCCTCAGCGTCTGGGACCC sequence GCCTGGGGGGTCCCTGAGA CCGGGCAGAGGGTCACCATC CTCTCCTGTGCAGCCTCTGG TCTTGTACTGGCTCTTCATC ATTCACCTTTAGCAATTAT TAATATTGGCAATAATGAT GATATGAGCTGGGTCCGCC GTCTCCTGGTACCAGCAGCT AGGCTCCAGGGAAGGGGCT CCCAGGAACGGCCCCCAAAC GGAGTGGGTCTCAGGGAT TCCTCATCTATGATGATAAT CTCTCATAGTAGTGGTAG AAGCGGCCAAGCGGGGTCC TAAATATTACGCTGATTC CTGACCGATTCTCTGGCTCC TGTAAAAGGTCGGTTCACC AAATCTGGCACCTCAGCCTC ATCTCCAGAGACAATTCCA CCTGGCCATCAGTGGGCTCC AGAACACGCTGTATCTGCA GGTCCGAGGATGAGGCTGAT AATGAACAGCCTGAGAGCC TATTACTGTGGTTCTTGGGA GAGGACACGGCCGTGTATT TGCTAGCCTGAATGCTTAT ACTGTGCGAAAGATGCTA GTCTTCGGCGGAGGCACCAA CTCCGCGTCCGCTGAAGC GCTGACGGTCCTAGGC (SEQ CTTTCGACTACTGGGGCCA ID NO: 120) GGGTACACTGGTCACCGTG AGCTCA (SEQ ID NO: 119)

A modified anti-EGFR scFv (heavy chain variable region: SEQ ID NO: 117 and light chain variable region: SEQ ID NO: 118) was prepared as described above, with the exception that the amino acid, G, at 44^(th) position of the heavy chain variable region (SEQ ID NO: 115) was substituted with C, and the amino acid, G, at 100^(th) position of the light chain variable region (SEQ ID NO: 116) was substituted with C. The amino acid location within the antibody complies with kabat numbering system. Such modifications (substitutions) can increase the stability of the anti-EGFR scFv.

<SEQ ID NO: 117: heavy chain variable region of modified anti-EGFR antibody E-2>

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYDMSWVRQAPGKCLEWV SGISHSSGSKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKDATPRPLKPFDYWGQGTLVTVSS

(wherein the sequences marked in bold type indicate CDRs, i.e., CDR-H1, CDR-H2, and CDR-H3, in sequence)

<SEQ ID NO: 118: light chain variable region of modified anti-EGFR antibody E-2>

QSVLTQPPSASGTPGQRVTISCTGSSSNIGNNDVSWYQQLPGTAPKLLIY DDNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCGSWDASLNAYV FGCGTKLTVLG

(wherein the sequences marked in bold type indicate CDRs, i.e., CDR-L1, CDR-L2, and CDR-L3, in sequence)

The thus obtained modified anti-EGFR scFv (including SEQ ID NO: 117 and SEQ ID NO: 118) was used to manufacture the following bispecific antibodies.

Example 2 Preparation of Anti-c-Met/Anti-EGFR Bispecific Antibody

The modified anti-EGFR scFv (including SEQ ID NO: 117 and SEQ ID NO: 118) prepared in the above Example 1 was fused at the c-terminal of Fc of the anti-c-Met antibody L3-1Y-IgG2 prepared in the above reference example 1. The fusion procedures are as follows.

A DNA segment having a base sequence (SEQ ID NO: 66) corresponding to the heavy chain of the anti-c-Met antibody L3-1Y-IgG2 prepared in above reference example 1 was inserted into a pcDNA™3.3-TOPO TA Cloning Kit (Cat no. 8300-01) which is included in OptiCHO™ Antibody Express Kit (Cat no. 12762-019) by Invitrogen Inc., and a DNA segment having a base sequence (SEQ ID NO: 68) corresponding to the light chain of the anti-c-Met antibody L3-1Y-IgG2 was inserted into a pOptiVEC™-TOPO TA Cloning Kit. Thereafter, the anti-EGFR scFv coding DNA prepared in Example 1 was fused at the c-terminal of Fc of L3-1Y-IgG2 inserted into pcDNA™3.3, using the coding DNA sequence of a linker peptide having 10 amino acid lengths consisting of (G4S)2, to construct vectors for the expression of bispecific antibodies.

The constructed vectors were each amplified using Qiagen Maxiprep kit (Cat no. 12662 and their temporary expressions were performed using Freestyle™ MAX 293 Expression System (invitrogen). A cell line used was 293 F cells, which were cultured in a suspension culture manner using FreeStyle™ 293 Expression Medium as a medium. One day before the temporary expression, the cells were prepared at a concentration of 5×10⁵ cells/ml and after 24 hours, their temporary expression started when the number of the cells reached 1×10⁶ cells/ml. Transfection was performed by a liposomal reagent method using Freestyle™ MAX reagent (Invitrogen). DNA was prepared in a 15-ml tube in a ratio of heavy chain DNA:light chain DNA=3:2 and mixed with 2 ml of OptiPro™ SFM (invtrogen) (A), and 100 μl of Freestyle™ MAX reagent and 2 ml of OptiPro™ SFM were mixed in another 15-ml tube (B), and after (A) and (B) were mixed and incubated for 15 min., the mixture solution was then slowly mixed into the cells which were prepared one day before. After the transfection was complete, the cells were cultured in a 37° C., 80% humidity, 8% CO₂, 130 rpm incubator for 5 days.

The cultured cells were centrifuged to obtain each 100 ml of supernatants, which were then purified using AKTA Prime (GE healthcare). The culture was flowed at a flow rate of 5 ml/min. onto the AKTA Prime installed with Protein A column (GE healthcare, 17-0405-03) to perform elution using an IgG elution buffer (Thermo Scientific, 21004). The buffer was replaced by a PBS buffer to finally obtain purified bispecific anti-c-Met/anti-EGFR antibodies.

The thus prepared anti-c-Met/anti-EGFR bispecific antibody in which the modified anti-EGFR scFv is fused at the c-terminal of L3-1Y-IgG2 was named ME22S.

Example 3 Properties of Anti-c-Met/Anti-EGFR Bispecific Antibody

To examine the property of the anti-c-Met/anti-EGFR bispecific antibody ME22S prepared in Example 2, 20 ug of ME22S was injected into HPLC system (WATERS 2695) equipped with TSKG3000SWXL column (Tosho) at the velocity of 0.5 ml/min, to conduct Size Exclusion Chromatography by HPLC.

The obtained results are shown in FIG. 2. As shown in FIG. 2, the anti-c-Met/anti-EGFR bispecific antibody ME22S forms a slight amount of soluble dimer (<1%)m, indicating that it is very stable molecule.

Example 4 Dual Binding of Anti-c-Met/Anti-EGFR Bispecific Antibody

To examine whether the anti-c-Met/anti-EGFR bispecific antibody recognizes both of the antigens, c-Met and EGFR, the experimentation using Biacore T100 (GE) was performed. An anti-6xHis antibody (#MAB050, R&D Systems) was immobilized onto a CM5 chip (#BR-1005-30, GE) using an amine coupling kit (#BR-1000-50, GE) according to the manufacturer's instructions. After the immobilization, c-Met-Fc (#358-MT/CF, R&D Systems) was injected thereto at the amount of 15 μg/m for 1 min. Then, the bispecific antibody ME22S prepared in Example 2 was injected at the amount of 20 nM for 1 min. Thereafter, EGFR-Fc (#344-ER, R&D Systems) was injected at 100 nM for 1 min and then, association/dissociation was observed.

In addition, the affinities of the prepared anti-c-Met/anti-EGFR bispecific antibody to the two types of antigens, c-Met and EGFR, were each identified using Biacore T100 (GE). A human Fab binder (GE Healthcare) was immobilized at the surface of a CM5 chip (#BR-1005-30, GE) according to the manufacturer's specifications. About 90 to 120 Ru of ME22S was captured, and c-Met-Fc (#358-MT/CF, R&D Systems) or EGFR-Fc (#344-ER, R&D Systems) were injected at various concentrations into the captured antibody. 10 mM Glycine-HCl (pH 1.5) solution was injected thereto to regenerate the surface. In order to measure affinity, the data obtained from this experiment was fitted using BIAevaluation software (GE Healthcare, Biacore T100 evaluation software).

The obtained results are shown in Table 5 and FIG. 3, wherein it is confirmed that ME22S binds to both of the two antigens, c-Met and EGFR.

TABLE 5 Antibody Antigen K_(D) (nM) k_(a) (1/Ms) k_(d) (1/s) ME22S cMet 0.05 1.3 × 10⁵ 5.5 × 10⁻⁵ EGFR 0.49 1.9 × 10⁵ 9.2 × 10⁻⁵

Example 5 Examination of Cancer Cell Proliferation Inhibition by Anti-c-Met/Anti-EGFR Bispecific Antibody

The cancer cell proliferation inhibition effects of the anti-c-Met/anti-EGFR bispecific antibody prepared in Example 2 were examined in stomach cancer cell lines SNU5 and SNU638, human skin cancer cell line A431, human lung cancer cell line NCI-H1993, and human head and neck cancer cell lines HN3 and K2D. SNU5, SNU638, A431, NCI-H1993, and HN3 cell lines were all purchased from ATCC. K2D cell line, which is a patient derived cell line, was donated from Medical College of Konkuk University.

A1 cells except A431 were incubated in RPMI1640 medium (#11875-093, Gibco) supplemented with 10%(v/v) FBS and 1%(v/v) Penicillin-Streptomycin under the conditions of 5% CO₂ and 37° C. . A431 cells were incubated in DMEM medium (#30-2002, ATCC) supplemented with 10%(v/v) FBS and 1%(v/v) Penicillin-Streptomycin under the conditions of 5% CO₂ and 37° C. . For cell proliferation assay, each cell line was sub-cultured at a concentration of 5×10³ cell/well in a 96-well plate, which was treated with the anti-c-Met/anti-EGFR bispecific antibody ME22S prepared in Example 2 in an amount of 0.25 ug (microgram)/ml (SNU5 cell line) or 5 μg/m (SNU638, A431, and NCI-H1993 cell lines), and cultured for 72 hours. A medium with no antibody was used as a negative control, and commercially available EGFR inhibitor Erbitux® (#ET509081213, Merck) treated group, L3-1Y-IgG2 antibody (prepared in reference example) treated group, and co-treated group of L3-1Y-IgG2 and Erbitux® were each used as positive controls. The amount of Erbitux® and L3-1Y-IgG2 were 0.25 μg/ml for SNU5 and 5 μg/m for SNU638, A431, and NCI-H1993 cell lines. HN3 and K2D cell lines were treated with ME22S by serially diluting from 10 μg/ml to 5fold dilution concentration and incubated for 72 hours.

After incubation, cell proliferation degrees were analyzed using Cell Counting Kit-8 assay (Dojindo Molecular Technologies, Gaithersburg, Md.) according to the manufacturer's instructions. In brief, after the incubation for 72 hours, 10 μl (microliter) of CCK8 solution was added to each well and after the additional incubation for 2.5 hours, absorption degrees were read at 450 nm using a microplate reader.

The obtained results are shown in FIGS. 4A to 4F. As seen in FIGS. 4A to 4F, the anti-c-Met/anti-EGFR bispecific antibody ME22S showed remarkable increases in cell proliferation inhibitory effects, compared to the cases treated individually with the anti-c-Met antibody L3-1Y-IgG2 and the anti-EGFR antibody Erbitux®. In particular, the anti-c-Met/anti-EGFR bispecific antibody ME22S showed excellent cell proliferation inhibitory effects, even compared to the co-treatment case (L3-1Y-IgG2+Erbitux®), which is not a form of bispecific antibody.

Example 6 Examination of Cancer Cell Proliferation Inhibition by Anti-c-Met/Anti-EGFR Bispecific Antibody in Resistance-Induced Cancer Cells

Cell lines N87(ATCC) and NCI-H820(ATCC) were incubated in RPMI1640 medium supplemented with 10%(v/v) FBS and 1%(v/v) Penicillin-Streptomycin under the condition of 5% CO₂ and 37° C. For cell proliferation assay, N87 cell line was sub-cultured at a concentration of 5×10³ cell/well in a 96-well plate, which was treated with 500 nM of Lapatinib (sc-353686, Santa Cruz Biotechnology) alone, 500 nM of Lapatinib and 1 μg/m of L3-1Y-IgG2 (co-treatment), 500 nM of Lapatinib and 1 μg/m of Erbitux® (co-treatment), and 500 nM of Lapatinib and 1 μg/m of ME-22S (co-treatment), and cultured for 72 hours. For resistance induction, 100 ng/ml of HGF (PGR 101-200, Pangen) was added to each of the above treatment groups and cultured for 72 hours together.

NCI-H820 cell line was sub-cultured at a concentration of 5×10³ cell/well in a 96-well plate, which was treated with 5 μg/m of ME-22S, and cultured for 72 hours. A medium with no antibody was used as a negative control, and commercially available EGFR inhibitor Erbitux® (#ET509081213, Merck) treated group, L3-1Y-IgG2 antibody (prepared in reference example) treated group, and co-treated group of L3-1Y-IgG2 and Erbitux® were each used as positive controls. The amount of each of Erbitux® and L3-1Y-IgG2 was 5 μg/m for each group. For resistance induction, 100 ng/ml of HGF (PGR 101-200, Pangen) was added to each of the above treatment groups and cultured for 72 hours together.

After incubation, cell proliferation degrees were analyzed using Cell Counting Kit-8 assay (Dojindo Molecular Technologies, Gaithersburg, Md.) according to the manufacturer's instructions. In brief, after the incubation for 72 hours, 10 μl of CCK8 solution was added to each well and after the additional incubation for 2.5 hours, absorption degrees were read at 450 nm using a microplate reader.

The obtained results are shown in FIG. 5. As seen in FIG. 5, the anti-c-Met/anti-EGFR bispecific antibody ME22S showed remarkable increases in cell proliferation inhibitory effects on N87 and H820 cell lines where a resistance is induced by HGF treatment as well as N87 and H820 cell lines treated with no HGF.

Example 7 C-Met and EGFR Activation Inhibitory Effect of Anti-c-Met/Anti-EGFR Bispecific Antibody

SNU638 cells were treated with Erbitux®, L3-1Y-IgG2 (Reference Example 1) and ME22S (Example 2), alone or in combination, for 40 minutes. Then each of HGF and EGF (236-EG-200, R&D systems) was added thereto at the amount of 100 ng/ml. Then, the cells were lysed with Complete Lysis-M (#04719956001, Roche), and the resulted cell lysates were collected and subject to SDS-PAGE electrophoresis.

After the electrophoresis, the proteins from the gels were transferred onto a nitrocellulose membrane (#LC2006, Invitrogen), which was then blocked with a skim milk (5% in TBST) at a room temperature for one hour. After blocking, for the primary antibody reaction, the membrane was treated with a 1:1000 dilution of anti-phospho c-Met antibody, anti-phospho EGFR antibody, anti-EGFR antibody, anti-phosphor Akt antibody, anti-Akt antibody (all available from Cell signaling technology), and anti-c-Met antibody (Abcam) in an amount of 10 μg/ml at a room temperature for two hours. After the primary antibody reaction, the membrane was washed three times with PBS for 5 min. and then, it was treated with a horseradish peroxidase attached secondary antibody (Cell signaling technology) against each primary antibody in an amount of 1 μg/ml at a room temperature for one hour. After the secondary antibody reaction, the membrane was washed three times with PBS for 5 min. and then sensitized with Enhanced chemiluminescence substrate (Thermo scientific) to measure the degree of antigen-antibody reaction by ImageQuant LAS system (GE Healthcare).

The obtained results are shown in FIG. 6. As shown in FIG. 6, the treatment of the anti-c-Met/anti-EGFR bispecific antibody ME22S results in increased c-Met phosphorylation inhibition and c-Met degradation, compared with treatment of anti-c-Met antibody L3-1Y-IgG2 alone, and L3-1Y-IgG2 and EGFR inhibitor Erbitux® in combination. In addition, when EGFR inhibitor Erbitux® is treated alone or in combination with L3-1Y-IgG2, EGFR phosphorylation inhibition is observed, but EGFR degradation is nearly not observed. When the anti-c-Met/anti-EGFR bispecific antibody ME22S is treated, EGFR degradation as well as EGFR phosphorylation inhibition is observed. Such results indicate that the anti-c-Met/anti-EGFR bispecific antibody ME22S has EGFR degradation activity as well as EGFR phosphorylation inhibitory activity, indicating that an EGFR inhibitor such as anti-EGFR antibody can possess a synergistic effect by forming a bispecific antibody with an anti-c-Met antibody, compared to an EGFR inhibitor alone.

Example 8 Co-Localization of c-Met and EGFR by Anti-c-Met/Anti-EGFR Bispecific Antibody

SNU638 cells (ATCC) were provided at the amount of 4×10⁴ cell/well, and treated with L3-1Y-IgG2 and anti-c-Met/anti-EGFR bispecific antibody ME22S alone or in combination at the amount of 5 μg/m per well (in the case of combination treatment, the amount of each antibody is 5 μg/m) under 37° C. for 4 hours. The cells were treated with 4%(v/v) formaldehyde for 15 minutes to be immobilized on a plate, and washed three times with PBS. Thereafter, the cells were treated with a blocking buffer (0.5% triton x-100 and 5% donkey serum) at a room temperature for one hour and then treated with a 1:100 dilution of primary antibodies against each of c-Met and EGFR (c-Met primary antibody; #FAB3582A, R&D systems, EGFR primary antibody; #5616, Cell signaling) against c-Met and EGFR, respectively in the amount of 100 μl, at 4° C. for 15 hours. After the cells were washed three time with PBS, they were treated with a 1:2000 dilution of a secondary antibody (#A21433, Invitrogen) in an amount of 100 ul at a room temperature for 1 hour and washed three times with PBS to prepare a plate with a mounting medium (#H-1200, Vector). The prepared cells were observed with a confocal microscope (Zeiss, LSM710).

The obtained results are shown in FIG. 7. As seen in FIG. 7, when EGFR inhibitor Erbitux® is treated alone, EGFR locates on cell membranes, and even when L3-1Y-IgG2 and Erbitux® are treated together, c-Met migrates to inside of the cell but EGFR still locates on cell membrane. However, when the anti-c-Met/anti-EGFR bispecific antibody ME22S is treated, both of c-Met and EGFR migrate to inside of the cells.

Example 9 Decrease in Expression of Target Receptor by Anti-c-Met/Anti-EGFR Bispecific Antibody

To examine decrease of expressed level of target receptors, c-Met and EGFR by ME22S, human stomach cancer cell line, MKN45 (ATCC) and SNU 638 (ATCC) were sub-cultured on 96-well plate, where the concentration of each cell line is 2×10³ cell/well. The cells were treated with each of L3-1Y-IgG2, Erbitux®, and ME22S, at the amount of 5 μg/ml, and cultured for 24 hours. A medium with no antibody was used as a negative control. After culture, the cells were lysed with Complete Lysis-M (#04719956001, Roche), and cell lysates were collected. Total cMet detection ELISA kit (DYC358E, R&D systems) was used for measuring the expression level of c-Met, and Total EGF Receptor ELISA kit (#7297, Cell Signaling) for measuring the expression level of EGFR, according to manufacturer's indications.

The obtained results are shown in FIG. 8. As shown in FIG. 8, L3-1Y-IgG2 and ME22S considerably decrease the expression level of c-Met. Erbitux® does not effect on the expression level of EGFR, whereas ME22S considerably decreases the expression level of EGFR as well as the expression level of c-Met.

Example 10 Inhibition of Cancer Metastasis by Anti-c-Met/Anti-EGFR Bispecific Antibody

Human stomach cancer cell line, SNU638 cells (ATCC) were sub-cultured on trans-well CIM-16 plate (Roche Applied Bioscience) in the concentration of 1×10⁵ cell/well. During the sub-culture, L3-1Y-IgG2, Erbitux®, and ME22S were treated alone or in combination, at the amount of 10 μg/ml, and to induce metastasis, HGF and EGF were treated at the amount of 100 ng/ml, respectively, simultaneously with the antibody treatment. The ratio of cancer metastasis was measured in real time using xCelligence RTCA DP instrument (Roche Applied Biosience).

The obtained results are shown in FIG. 9. As shown in FIG. 9, the treatment of Erbitux® alone has no effect in inhibiting cancer metastasis, but the treatment L3-1Y-IgG2 alone and the combination treatment of L3-1Y-IgG2 and Erbitux® result in inhibiting cancer metastasis to the ratio of about 30%. However, ME22S exhibits more excellent inhibition ratio of cancer metastasis as about 45%, indicating that the anti-c-Met/anti-EGFR bispecific antibody is more effective in inhibition of cancer metastasis.

Example 11 Cancer Cell Inhibition Effect of Anti-c-Met/Anti-EGFR Bispecific Antibody

SNU5 cells (ATCC) were injected into dorsal subcutis of 5-6 week old CB.17-SCID mice (Shanghai SLAC Laboratory Animal Co. Ltd.) at the amount of 3×10⁶ cell/mouse, to prepare tumor models. When the tumor volume reaches 100 mm³, 1 mg/kg of L3-1Y-IgG2 and 1 mg/kg of anti-c-Met/anti-EGFR bispecific antibody ME22S were intravenously administered alone or in combination once a week for 4 weeks in total. A group where PBS is intravenously administered thereto was used as a negative control, and a group where 10 mg/kg of an anticancer drug, Irinotecan (Pfizer Inc.), was intravenously administered thereto twice a week for 4 weeks in total, was used as a positive control. The tumor size (length×breadth×height) was measured twice each week, and at the last week, the mice were autopsied.

The obtained tumor size is shown in FIG. 10. As shown in FIG. 10, when L3-1Y-IgG2 is treated alone, the tumor growth is inhibited and the final tumor size is nearly not increased from the initial size of 100 mm³, and the positive control shows the similar results where the final tumor size is about 72 mm³. However, when ME22S is treated, the tumor size becomes significantly decreased from 7 days after the administration, and the final tumor size is about 12 mm³. These results indicate that the anti-c-Met/anti-EGFR bispecific antibody has more increased inhibitory effect on cancer cell growth compared to L3-1Y-IgG2 and pre-existing drug, Irinotecan.

All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. 

What is claimed is:
 1. A polypeptide comprising one amino acid sequence, or a combination of two or more amino acid sequences, selected from the group consisting of SEQ ID NOs: 109 to
 114. 2. The polypeptide according to claim 1, wherein the polypeptide comprises: SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 116, SEQ ID NO: 118, or a combination thereof.
 3. An anti-EGFR antibody or an antigen-binding fragment thereof, comprising: at least one heavy chain complementarity determining region selected from the group consisting of a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 111; at least one light chain complementarity determining region selected from the group consisting of a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 112, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 113, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 114; or a combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region.
 4. The anti-EGFR antibody or an antigen-binding fragment thereof according to claim 3, comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, or a combination thereof
 5. The anti-EGFR antibody or an antigen-binding fragment thereof according to claim 4, wherein the anti-EGFR antibody or an antigen-binding fragment is an anti-EGFR scFv comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, or a combination thereof.
 6. An anti-c-Met/anti-EGFR bispecific antibody comprising an anti-c-Met antibody or an antigen-binding fragment thereof and an anti-EGFR antibody or an antigen-binding fragment thereof, wherein the anti-c-Met antibody or an antigen-binding fragment thereof binds to an epitope comprising 5 or more contiguous amino acids of SEQ ID NO: 79; and the anti-EGFR antibody or an antigen-binding fragment thereof comprises: at least one heavy chain complementarity determining region selected from the group consisting of a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 111; at least one light chain complementarity determining region selected from the group consisting of a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 112, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 113, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 114; or a combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region.
 7. The anti-c-Met/anti-EGFR bispecific antibody according to claim 6, wherein the antigen-binding fragment of the anti-c-Met antibody or the anti-EGFR antibody is selected from the group consisting of scFv, (scFv)2, scFvFc, Fab, Fab′, and F(ab′)2.
 8. The anti-c-Met/anti-EGFR bispecific antibody according to claim 6, wherein the anti-c-Met antibody or the antigen-binding fragment thereof binds to an epitope having 5 to 19 contiguous amino acids of SEQ ID NO: 71, and the epitope comprises the amino acid sequence of SEQ ID NO:
 73. 9. The anti-c-Met/anti-EGFR bispecific antibody according to claim 6, wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises: at least one heavy chain complementarity determining region selected from the group consisting of (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 2, or an amino acid sequence comprising 8-19 consecutive amino acids within SEQ ID NO: 2 including the amino acid residues from the 3^(rd) to 10^(th) positions of SEQ ID NO: 2; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 85, or an amino acid sequence comprising 6-13 consecutive amino acids within SEQ ID NO: 85 including the amino acid residues from the 1^(st) to 6^(th) positions of SEQ ID NO: 85; at least one light chain complementarity determining region (CDR) selected from the group consisting of (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7, (b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8, and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 86, or an amino acid sequence comprising 9-17 consecutive amino acids within SEQ ID NO: 89 including the amino acid residues from the 1^(st) to 9^(th) positions of SEQ ID NO: 89; or a combination of the at least one heavy chain complementarity determining region and at least one light chain complementarity determining region.
 10. The anti-c-Met/anti-EGFR bispecific antibody according to claim 9, wherein the CDR-H1 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24, the CDR-H2 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 25, or SEQ ID NO: 26, the CDR-H3 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: 85, the CDR-L1 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 106, the CDR-L2 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 11, SEQ ID NO: 34, SEQ ID NO: 35, or SEQ ID NO: 36, and the CDR-L3 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 37, SEQ ID NO: 86, or SEQ ID NO:
 89. 11. The anti-c-Met/anti-EGFR bispecific antibody according to claim 9, wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising a polypeptide (CDR-H1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 22, 23, and 24, a polypeptide (CDR-H2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 25, and 26, and a polypeptide (CDR-H3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 27, 28, and 85; and a light chain variable region comprising a polypeptide (CDR-L1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 29, 30, 31, 32, 33 and 106, a polypeptide (CDR-L2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 34, 35, and 36, and a polypeptide (CDR-L3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs 12, 13, 14, 15, 16, 37, 86, and
 89. 12. The anti-c-Met/anti-EGFR bispecific antibody according to claim 6, wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17, 74, 87, 90, 91, 92, 93, or 94, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, 19, 20, 21, 75, 88, 95, 96, 97, 98, 99, or 107, or a combination of the heavy chain variable region and the light chain variable region.
 13. The anti-c-Met/anti-EGFR bispecific antibody according to claim 6, wherein the anti-c-Met antibody comprises: a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 62, the amino acid sequence from the 18^(th) to 462^(nd) positions of SEQ ID NO: 62, SEQ ID NO: 64, the amino acid sequence from the 18^(th) to 461^(st) positions of SEQ ID NO: 64, SEQ ID NO: 66, and the amino acid sequence from the 18^(th) to 460^(th) positions of SEQ ID NO: 66; and a light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 68, the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 68, SEQ ID NO: 70, the amino acid sequence from the 21^(st) to 240^(th) positions of SEQ ID NO: 70, and SEQ ID NO:
 108. 14. The anti-c-Met/anti-EGFR bispecific antibody according to claim 6, wherein the anti-EGFR antibody or the antigen-binding fragment thereof comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117, a light chain variable region comprising the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, or a combination thereof.
 15. The anti-c-Met/anti-EGFR bispecific antibody according to claim 6, wherein the anti-EGFR antibody or the antigen-binding fragment thereof is linked to C-terminus of the anti-c-Met antibody.
 16. A method of preventing or treating a cancer comprising administering the anti-EGFR antibody or the antigen-binding fragment thereof of claim 3 to a subject in need of preventing or treating a cancer.
 17. A method of preventing or treating a cancer comprising administering the anti-c-Met/anti-EGFR bispecific antibody of claim 6 to a subject in need of preventing or treating a cancer.
 18. A pharmaceutical composition comprising the anti-EGFR antibody or the antigen-binding fragment thereof of claim 3 and a pharmaceutically acceptable carrier.
 19. A pharmaceutical composition comprising the anti-c-Met/anti-EGFR bispecific antibody of claim 6 and a pharmaceutically acceptable carrier. 